STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 145634

TO: Jennifer Kim **Location: 4b02 / 4b18** **Wednesday, February 23, 2005** **Art Unit: 1617** **Phone: 272-0628** **Serial Number: 10 / 029424**	**From: Jan Delaval** **Location: Biotech-Chem Library** **Rem 1a51** **Phone: 272-2504** **jan.delaval@uspto.gov**

Search Notes

Jan Delevoryas

Access DB# 145634

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name Jennifer Kim Examiner #: 77469 Date: 2/18/05
Art Unit: 1617 Phone Number 30 20628 Serial Number 10/029,424
Mail Box and Bldg Room Location 4B02 Remsen Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Method of treating hormonal deficiencies in woman undergoing ~~estrogen replacement~~ therapy

Inventors (please provide full names): Leonard et al.

Earliest Priority Filing Date: 12/22/2000

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

1) Please seach claim 32

2) Please display structure & registry # of the cpd 1-10 in claim 32. (Please # each cpd as 1-10)

HIV,

Jan.

STAFF USE ONLY

Searcher: Jan	Type of Search	Vendors and cost where applicable	
Searcher Phone #: 27504	NA Sequence (#)	STN ✓	
Searcher Location:	AA Sequence (#)	Dialog	
Date Searcher Picked Up: 2/23/05	Structure (#)	Questel/Orbit	
Date Completed: 2/23/05	Bibliographic ✓	Lexis/Nexis	
Searcher Prep & Review Time:	Litigation	Sequence Systems	
Online Prep Time: 15	Fulltext	WWW/Internet	
Online Time: +45	Patent Family	Other (specify)	
	Other		

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 15:44:50 ON 23 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 FEB 2005  HIGHEST RN 835870-69-4
DICTIONARY FILE UPDATES:  22 FEB 2005  HIGHEST RN 835870-69-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d ide can l5

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   53-16-7  REGISTRY
CN   Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Estrone (8CI)
OTHER NAMES:
CN   (+)-Estrone
CN   Δ1,3,5(10)-Estratrien-3-ol-17-one
CN   1,3,5(10)-Estratrien-3-ol-17-one
CN   3-Hydroxy-17-keto-estra-1,3,5-triene
CN   3-Hydroxyestra-1,3,5(10)-trien-17-one
CN   3-Hydroxyestra-1,3,5(10)-triene-17-one
CN   3-Hydroxyoestra-1,3,5(10)-trien-17-one
CN   Aquacrine
CN   Crinovaryl
CN   Cristallovar
CN   Crystogen
CN   Destrone
CN   Disynformon
CN   Endofolliculina
CN   Estron
CN   Estrovarin
CN   Estrugenone
CN   Estrusol
CN   Femestrone Inj.
CN   Femestrone injection
CN   Femidyn
CN   Fermidyn
CN   Folikrin
CN   Folipex
CN   Folisan
CN   Follestrine
CN   Follestrol
CN   Follicular hormone
CN   Folliculin
CN   Folliculin (steroid)
CN   Follicunodis
```

CN Follidrin
CN Glandubolin
CN Hiestrone
CN Hormofollin
CN Hormovarine
CN Kestrone
CN Ketodestrin
CN Ketohydroxyestrin
CN Kolpon
CN Menagen
CN Menformon
CN NSC 9699
CN Oestrin
CN Oestroform
CN Oestrone
CN Oestroperos
CN Ovifollin
CN Perlatan
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS STEREOSEARCH
DR 37242-41-4
MF C18 H22 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10760 REFERENCES IN FILE CA (1907 TO DATE)
259 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
10766 REFERENCES IN FILE CAPLUS (1907 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:162670

REFERENCE 2: 142:162271

REFERENCE 3: 142:162267

REFERENCE 4: 142:156210

REFERENCE 5: 142:156209

REFERENCE 6: 142:153029

REFERENCE 7: 142:134783

REFERENCE 8: 142:134175

REFERENCE 9: 142:133675

REFERENCE 10: 142:127738

=> d ide can l6

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **474-86-2** REGISTRY
CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Equilin (6CI, 7CI)
OTHER NAMES:
CN 1,3,5,7-Estratetraen-3-ol-17-one
CN 3-Hydroxyestra-1,3,5(10),7-tetraen-17-one
CN 7-Dehydroestrone
CN NSC 10971
FS STEREOSEARCH
MF C18 H20 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

436 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
438 REFERENCES IN FILE CAPLUS (1907 TO DATE)
41 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:70104

REFERENCE 2: 142:33812

REFERENCE 3: 141:360695

REFERENCE 4: 141:344068

REFERENCE 5: 141:343686

REFERENCE 6: 141:314487

REFERENCE 7: 141:248468

REFERENCE 8: 141:154709

REFERENCE 9: 141:94343

REFERENCE 10: 141:33322

=> d ide can l7

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **474-87-3** REGISTRY

CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Δ8,9-Dehydroestrone
CN Δ8-Dehydroestrone
CN Δ8-Isoequilin
CN 8,9-Dehydroestrone
FS STEREOSEARCH
MF C18 H20 O2
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

49 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
49 REFERENCES IN FILE CAPLUS (1907 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:360695

REFERENCE 2: 141:344068

REFERENCE 3: 141:314487

REFERENCE 4: 141:94343

REFERENCE 5: 141:1503

REFERENCE 6: 139:396107

REFERENCE 7: 139:375242

REFERENCE 8: 139:302513

REFERENCE 9: 139:281289

REFERENCE 10: 139:271455

=> d ide can l8

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **57-91-0** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 17α-Estradiol (8CI)
OTHER NAMES:
CN α-Estradiol
CN 1,3,5-Estratriene-3,17α-diol
CN 13β-Methyl-1,3,5(10)-gonatriene-3,17α-diol
CN 17-Epiestradiol
CN 17α-Oestradiol
CN 3,17-Dihydroxyestratriene
CN 3,17α-Dihydroxyestra-1,3,5(10)-triene
CN 3,17α-Dihydroxyoestra-1,3,5(10)-triene
CN Alfatradiol
CN Epiestradiol
CN Epiestrol
CN Estra-1,3,5(10)-triene-3,17α-diol
CN NSC 20293
CN Oestra-1,3,5(10)-triene-3,17α-diol
FS STEREOSEARCH
MF C18 H24 O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PRP (Properties)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1269 REFERENCES IN FILE CA (1907 TO DATE)
33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1270 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:127686

REFERENCE 2: 142:107663

REFERENCE 3: 142:70007

REFERENCE 4: 142:69327

REFERENCE 5: 142:68505

REFERENCE 6: 142:49386

REFERENCE 7: 142:49373

REFERENCE 8: 142:49360

REFERENCE 9: 142:33812

REFERENCE 10: 142:27729

=> d ide can l9

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **3563-27-7** REGISTRY
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10),7-tetraene-3,17β-diol (6CI, 7CI, 8CI)
OTHER NAMES:
CN β-Dihydroequilin
CN 17β-Dihydroequilin
CN 7-Dehydroestradiol
CN NSC 12170
FS STEREOSEARCH
MF C18 H22 O2
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, MRCK*, MSDS-OHS, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

109 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
109 REFERENCES IN FILE CAPLUS (1907 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:360695

REFERENCE 2: 141:314487

REFERENCE 3: 141:94343

REFERENCE 4: 141:1503

REFERENCE 5: 140:363029

REFERENCE 6: 139:375242

REFERENCE 7: 139:302513

REFERENCE 8: 139:281289

REFERENCE 9: 139:271455

REFERENCE 10: 139:224682

=> d ide can l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **651-55-8** REGISTRY
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10),7-tetraene-3,17α-diol (8CI)

OTHER NAMES:
CN α-Dihydroequilin
CN α-Equilol
CN 17α-Dihydroequilin
FS STEREOSEARCH
MF C18 H22 O2
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMLIST, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, MSDS-OHS, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); FORM (Formation, nonpreparative)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

104 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
105 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:360695

REFERENCE 2: 141:314487

REFERENCE 3: 141:94343

REFERENCE 4: 141:1503

REFERENCE 5: 140:139705

REFERENCE 6: 139:375242

REFERENCE 7: 139:302513

REFERENCE 8: 139:281289

REFERENCE 9: 139:271455

REFERENCE 10: 139:57888

=> d ide can l11

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **50-28-2** REGISTRY
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estradiol (8CI)
OTHER NAMES:
CN (+)-3,17β-Estradiol
CN β-Estradiol
CN 13β-Methyl-1,3,5(10)-gonatriene-3,17β-ol
CN 17β-Estradiol
CN 17β-Oestradiol
CN 3,17-Epidihydroxyestratriene
CN 3,17β-Dihydroxyestra-1,3,5(10)-triene
CN 3,17β-Estradiol
CN Absorlent Matrix
CN Aerodiol
CN Altrad
CN Aquadiol
CN Bardiol
CN Beta-estradiol
CN Climaderm
CN Climara
CN Compudose
CN Compudose 200
CN Compudose 365
CN Corpagen
CN Dermestril
CN Dihydrofollicular hormone
CN Dihydrofolliculin
CN Dihydromenformon
CN Dihydrotheelin
CN Dihydroxyestrin
CN Dimenformon
CN Diogyn
CN Diogynets
CN Divigel
CN E 2
CN Encore
CN Epiestriol 50
CN Estra-1,3,5(10)-triene-3,17-diol, (17β)-
CN Estra-1,3,5(10)-triene-3,17β-diol
CN Estrace
CN Estraderm
CN Estraderm TTS
CN Estraderm TTS 100
CN Estraderm TTS 50
CN Estradot
CN Estraldine
CN Estring Vaginal Ring
CN Estroclim
CN Estroclim 50
CN Estrogel
CN Estrogel HBF
CN Estrovite
CN Evorel
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for

DISPLAY
FS STEREOSEARCH
MF C18 H24 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

54116 REFERENCES IN FILE CA (1907 TO DATE)
983 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
54182 REFERENCES IN FILE CAPLUS (1907 TO DATE)
12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:162670

REFERENCE 2: 142:162267

REFERENCE 3: 142:162088

REFERENCE 4: 142:156210

REFERENCE 5: 142:156209

REFERENCE 6: 142:154840

REFERENCE 7: 142:153320

REFERENCE 8: 142:153270

REFERENCE 9: 142:153168

REFERENCE 10: 142:153029

=> d ide can l12

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **517-09-9** REGISTRY
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Equilenin (6CI)
OTHER NAMES:
CN (+)-Equilenin
CN 3-Hydroxyestra-1,3,5(10),6,8-pentaen-17-one
CN d-Equilenin
CN Equilenine
CN NSC 9901
FS STEREOSEARCH
MF C18 H18 O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

483 REFERENCES IN FILE CA (1907 TO DATE)
23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
484 REFERENCES IN FILE CAPLUS (1907 TO DATE)
29 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:93155

REFERENCE 2: 142:33812

REFERENCE 3: 141:389284

REFERENCE 4: 141:383841

REFERENCE 5: 141:380063

REFERENCE 6: 141:360695

REFERENCE 7: 141:343686

REFERENCE 8: 141:314487

REFERENCE 9: 141:154709

REFERENCE 10: 141:94343

=> d ide can l13

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **6639-99-2** REGISTRY
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10),6,8-pentaene-3,17α-diol (6CI, 7CI, 8CI)
OTHER NAMES:
CN α-Dihydroequilenin
CN 17α-Dihydroequilenin
CN Estra-1,3,5,7,9-pentaene-3,17α-diol
CN NSC 12171
FS STEREOSEARCH
DR 73088-21-8
MF C18 H20 O2
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CHEMLIST, DDFU, DRUGU, IFICDB, IFIPAT, IFIUDB, IPA, MSDS-OHS, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); FORM (Formation, nonpreparative)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

103 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
103 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:360695

REFERENCE 2: 141:314487

REFERENCE 3: 141:94343

REFERENCE 4: 141:1503

REFERENCE 5: 140:157620

REFERENCE 6: 139:375242

REFERENCE 7: 139:302513

REFERENCE 8: 139:281289

REFERENCE 9: 139:271455

REFERENCE 10: 139:57888

=> d ide can l14

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **1423-97-8** REGISTRY
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN Estra-1,3,5(10),6,8-pentaene-3,17β-diol (6CI, 7CI)
CN Estra-1,3,5,7,9-pentaene-3,17β-diol (8CI)
OTHER NAMES:
CN β-Dihydroequilenin
CN 17β-Dihydroequilenin
FS STEREOSEARCH
MF C18 H20 O2
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CHEMLIST, DDFU, DRUGU, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

105 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
105 REFERENCES IN FILE CAPLUS (1907 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:314487

REFERENCE 2: 141:94343

REFERENCE 3: 141:65339

REFERENCE 4: 141:1503

REFERENCE 5: 140:157620

REFERENCE 6: 139:375242

REFERENCE 7: 139:302513

REFERENCE 8: 139:281289

REFERENCE 9: 139:271455

REFERENCE 10: 139:79288

=> => d ide can l17

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **53-39-4** REGISTRY
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Oxa-5α-androstan-3-one, 17β-hydroxy-17-methyl- (7CI, 8CI)
CN 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5α,17β)-
OTHER NAMES:
CN 17-Methyl-2-oxa-5α-androstan-17β-ol-3-one
CN 17β-Hydroxy-17-methyl-2-oxa-5α-androstan-3-one
CN 17β-Hydroxy-17α-methyl-2-oxa-5α-androstan-3-one
CN 8075CB
CN Anavar
CN Lonavar
CN NSC 67068
CN Oxandren
CN Oxandrin
CN Oxandrolone
CN Protivar
CN Provitar
CN SC 11585
CN Vasorome
FS STEREOSEARCH
MF C19 H30 O3
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); PRP (Properties)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

268 REFERENCES IN FILE CA (1907 TO DATE)
11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
268 REFERENCES IN FILE CAPLUS (1907 TO DATE)
22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:141282

REFERENCE 2: 142:120512

REFERENCE 3: 142:86805

REFERENCE 4: 142:32284

REFERENCE 5: 141:388999

REFERENCE 6: 141:375642

REFERENCE 7: 141:332356

REFERENCE 8: 141:325783

REFERENCE 9: 141:313434

REFERENCE 10: 141:308745

=> d ide can l18

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **434-07-1** REGISTRY
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5α-Androstan-3-one, 17β-hydroxy-2-(hydroxymethylene)-17-methyl- (6CI, 8CI)
OTHER NAMES:
CN 17-Beta-Hydroxy-2-hydroxymethylene-17-alpha-methyl-3-androstanone
CN 17α-Methyl-2-hydroxymethylene-17-hydroxy-5α-androstan-3-one
CN 17β-Hydroxy-2-(hydroxymethylene)-17-methyl-5α-androstan-3-one
CN 17β-Hydroxy-2-(hydroxymethylene)-17α-methyl-5α-androstan-3-one
CN 2-(Hydroxymethylene)-17-methyldihydrotestosterone
CN 2-Hydroxymethylene-17α-methyl-17β-hydroxy-3-androstanone
CN 2-Hydroxymethylene-17α-methylandrostan-17β-ol-3-one
CN 2-Hydroxymethylene-17β-hydroxy-17α-methyl-5α-androstan-3-one

CN Adroyd
CN Anadrol
CN Anapolan 50
CN Anapolon
CN Anasteron
CN Anasteronal
CN Anasterone
CN Becorel
CN C.I. 406
CN HMD
CN Nastenon
CN NSC-26198
CN Oxymethenolone
CN Oxymetholone
CN Pardroyd
CN Plenastril
CN Protanabol
CN Roboral
CN Synasteron
CN Synasteron 50
FS STEREOSEARCH
MF C21 H32 O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent; Report
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study)

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

338 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
338 REFERENCES IN FILE CAPLUS (1907 TO DATE)
35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:149880

REFERENCE 2: 142:120512

REFERENCE 3: 142:86805

REFERENCE 4: 141:390068

REFERENCE 5: 141:388923

REFERENCE 6: 141:282811

REFERENCE 7: 141:135530

REFERENCE 8: 141:42919

REFERENCE 9: 141:28671

REFERENCE 10: 140:193319

=> d ide can l19

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **10418-03-8** REGISTRY
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2'H-5α-Androst-2-eno[3,2-c]pyrazol-17β-ol, 17-methyl- (8CI)
CN Cyclopenta[7,8]phenanthro[2,3-c]pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl- (6CI, 7CI)
CN Cyclopenta[7,8]phenanthro[2,3-c]pyrazole, 2'H-androst-2-eno[3,2-c]pyrazol-17-ol deriv.
OTHER NAMES:
CN 17-Methyl-5α-androstano[3,2-c]pyrazol-17β-ol
CN 17-Methyl-pyrazolo[4',3':2,3]-5α-androstan-17β-ol
CN 17α-Methyl-17β-hydroxy-5α-androstano(3,2-c)pyrazole
CN 17β-Hydroxy-17-methyl-5α-androstano[3,2-c]pyrazole
CN 17β-Hydroxy-17α-methyl-5α-androstano[3,2-c]pyrazole
CN Anabol
CN Androstanazol
CN Androstanazole
CN Androstanazolestanazol
CN Estazol
CN NSC 233046
CN NSC 43193
CN Stanazolol
CN Stanozolol
CN Stromba
CN Strombaject
CN Tevabolin
CN Win 14833
CN Winstroid
CN Winstrol
CN Winstrol Depot

CN Winstrol V
AR 302-96-5
FS STEREOSEARCH
DR 17966-55-1, 69353-49-7
MF C21 H32 N2 O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IPA, MEDLINE, MRCK*, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PRP (Properties)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

428 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
429 REFERENCES IN FILE CAPLUS (1907 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:120512

REFERENCE 2: 142:86805

REFERENCE 3: 142:69995

REFERENCE 4: 141:420535

REFERENCE 5: 141:308751

REFERENCE 6: 141:308745

REFERENCE 7: 141:282811

REFERENCE 8: 141:236865

REFERENCE 9: 141:220275

REFERENCE 10: 141:212833

=> d ide can 120

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **17230-88-5** REGISTRY
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 17α-Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol (8CI)
CN 1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol, 1-ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl- (7CI)
CN 1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazole, pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol deriv.
OTHER NAMES:
CN 17α-Pregna-2,4-dien-20-yne-[2,3-d]isoxazole-17β-ol
CN Bonzol
CN Chronogyn
CN Cyclomen
CN Danazol
CN Danazolum
CN Danocrine
CN Danol
CN Danovaol
CN Danzol
CN Ladogal
CN NSC 270916
CN Win 17757
CN Winobanin
FS STEREOSEARCH
MF C22 H27 N O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

658 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
659 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 142:127711

REFERENCE 2: 142:120512

REFERENCE 3: 142:120319

REFERENCE 4: 142:107349

REFERENCE 5: 142:106811

REFERENCE 6: 142:28161

REFERENCE 7: 142:16869

REFERENCE 8: 142:11382

REFERENCE 9: 142:11380

REFERENCE 10: 141:388765

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:46:15 ON 23 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Feb 2005 VOL 142 ISS 9
FILE LAST UPDATED: 22 Feb 2005 (20050222/ED)

This file contains CAS Registry Numbers for easy and accurate

substance identification.

=> d all hitstr tot 160

L60 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:818295 HCAPLUS
DN 139:302513
ED Entered STN: 17 Oct 2003
TI **Hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**
IN **Leonard, Thomas W.; Waldon, R. Forrest**
PA **Endeavor Pharmaceuticals, USA**
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-56
CC 2-4 (Mammalian Hormones)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084547	A1	20031016	WO 2003-US2873	20030131
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003216366	A1	20031120	US 2003-356242	20030131
	EP 1494679	A1	20050112	EP 2003-746025	20030131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-369905P	P	20020403		
	WO 2003-US2873	W	20030131		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003084547	ICM	A61K031-56

AB The present invention includes methods for treating vasomotor symptoms associated with human **menopause** through the administration of estrogenic compds. The methods presented may include starting estrogen therapy at a high dose, and then lowering the dose once therapy has been shown to be effective. Progestins and androgenic compound can addnl. be combined with the therapy.
ST estrogen **hormone replacement therapy** **menopause** disorder vasomotor symptom
IT Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; **hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)
IT **Menopause**
(**disorder, hot flash; hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)
IT **Menopause**
(**disorder; hormone replacement**

therapy with estrogenic compound to treat vasomotor symptoms associated with **menopause**)

IT Skin, disease
(dry; **hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)

IT Hair, disease
Vagina, disease
(dryness; **hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)

IT Bladder, disease
Drug delivery systems
Hormone replacement therapy
Human
Insomnia
(**hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)

IT Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)

IT Androgens
Progestogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in conjunction with **estrogen replacement therapy**; **hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)

IT Mental disorder
(mood-affecting; **hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)

IT **50-28-2, 17β -Estradiol**, biological studies **53-16-7, Estrone**, biological studies 57-63-6, Ethinyl **estradiol 57-91-0, 17α -Estradiol 474-86-2, Equilin 474-87-3**, Δ8,9-Dehydroestrone **517-09-9**, Equilenin **651-55-8, 17α -Dihydroequilin** 979-32-8, **Estradiol** valerate **1423-97-8, 17β -Dihydroequilenin 3563-27-7, 17β -Dihydroequilin 6639-99-2, 17α -Dihydroequilenin** 23392-54-3, 17β-Δ8,9-Dehydroestradiol 162707-56-4, 17α-Δ8,9-Dehydroestradiol 360792-45-6, 6-Hydroxy-**17β -dihydroequilenin** 360792-47-8, 6-Hydroxyequilenin 360796-54-9, 6-Hydroxy-**17α -dihydroequilenin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)

IT **53-39-4, Oxandrolone 434-07-1, Oxymetholone** 521-18-6, Stanolone **10418-03-8, Stanozolol 17230-88-5, Danazol**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in conjunction with **estrogen replacement**

therapy; hormone replacement therapy with estrogenic compound to treat vasomotor symptoms associated with **menopause**)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Hirvonen; US 5043331 A 1991 HCAPLUS

(2) Plunkett; US 36247 A 1999 HCAPLUS

IT **50-28-2**, **17β -Estradiol**, biological studies **53-16-7**, **Estrone**, biological studies **57-91-0**, **17α -Estradiol** **474-86-2**, **Equilin** **474-87-3**, Δ8,9-Dehydroestrone **517-09-9**, Equilenin **651-55-8**, **17α -Dihydroequilin** **1423-97-8**, **17β -Dihydroequilenin** **3563-27-7**, **17β -Dihydroequilin** **6639-99-2**, **17α -Dihydroequilenin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 57-91-0 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-86-2 HCAPLUS
CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-87-3 HCAPLUS
CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517-09-9 HCAPLUS
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651-55-8 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1423-97-8 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3563-27-7 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6639-99-2 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **53-39-4, Oxandrolone 434-07-1,**
Oxymetholone 10418-03-8, Stanozolol
17230-88-5, Danazol
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in conjunction with **estrogen replacement therapy; hormone replacement therapy** with estrogenic compound to treat vasomotor symptoms associated with **menopause**)
RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:796313 HCAPLUS
DN 139:271455
ED Entered STN: 10 Oct 2003
TI Estrogens and non-aromatizing androgens pharmaceutical compositions for the treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**
IN **Leonard, Thomas W.; Waldon, R. Forrest**
PA USA
SO U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO

DT Patent
LA English
IC ICM A61K031-56
NCL 514170000; 514171000
CC 2-4 (Mammalian Hormones)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003191096	A1	20031009	US 2002-268008	20021009
	WO 2003084546	A1	20031016	WO 2003-US2871	20030131
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1494678	A1	20050112	EP 2003-746024	20030131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-369635P	P	20020403		
	US 2002-268008	A	20021009		
	WO 2003-US2871	W	20030131		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003191096	ICM	A61K031-56
	NCL	514170000; 514171000

AB The present invention combines the administration of estrogens with the administration of non-aromatizing androgens to treat frailty and sexual dysfunction in women undergoing **estrogen replacement therapy.**

ST estrogen androgen **hormone replacement therapy**
frailty sexual dysfunction

IT Progestogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-administered with the hormonal therapy; estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

IT Sexual behavior
(disorder; estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

IT **Hormone replacement therapy**
Human
(estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

IT Androgens
Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

IT Bone
(strength increase; estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction

of women undergoing **estrogen replacement therapy**)

IT Muscle, disease
(weakness; estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

IT **50-28-2**, **17β -Estradiol**,
biological studies **53-16-7**, **Estrone**, biological studies **53-39-4**, **Oxandrolone** 57-63-6, Ethinyl **estradiol 57-91-0**, **17α -Estradiol 434-07-1**, **Oxymetholone 474-86-2**, **Equilin 474-87-3**, Δ8,9-Dehydroestrone **517-09-9**, Equilenin 521-18-6, Stanolone **651-55-8**, **17α -Dihydroequilin** 979-32-8, **Estradiol** valerate **1423-97-8**, **17β -Dihydroequilenin 3563-27-7**, **17β -Dihydroequilin 6639-99-2**, **17α -Dihydroequilenin 10418-03-8**, **Stanozolol 17230-88-5**, **Danazol** 23392-54-3, 17βΔ8,9-Dehydroestradiol 162707-56-4, 17αΔ8,9-Dehydroestradiol 360792-47-8, 6-Hydroxyequilenin 360796-54-9, 6-Hydroxy-**17α -dihydroequilenin**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

IT **50-28-2**, **17β -Estradiol**,
biological studies **53-16-7**, **Estrone**, biological studies **53-39-4**, **Oxandrolone 57-91-0**, **17α -Estradiol 434-07-1**, **Oxymetholone 474-86-2**, **Equilin 474-87-3**, Δ8,9-Dehydroestrone **517-09-9**, Equilenin **651-55-8**, **17α -Dihydroequilin 1423-97-8**, **17β -Dihydroequilenin 3563-27-7**, **17β -Dihydroequilin 6639-99-2**, **17α -Dihydroequilenin 10418-03-8**, **Stanozolol 17230-88-5**, **Danazol**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogens and non-aromatizing androgens pharmaceutical compns. for treatment of frailty and sexual dysfunction of women undergoing **estrogen replacement therapy**)

RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS

CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-91-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 474-86-2 HCAPLUS
CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-87-3 HCAPLUS
CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517-09-9 HCAPLUS
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651-55-8 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1423-97-8 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3563-27-7 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6639-99-2 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:888571 HCAPLUS
DN 137:363705
ED Entered STN: 22 Nov 2002
TI Treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens
IN **Leonard, Thomas W.**

PA **Endeavor Pharmaceuticals, USA**
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-565
ICS A61K031-57; A61P015-12
CC 2-4 (Mammalian Hormones)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092102	A2	20021121	WO 2002-US15690	20020516
	WO 2002092102	A3	20030320		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003004145	A1	20030102	US 2002-147366	20020516
	EP 1390038	A2	20040225	EP 2002-736946	20020516
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004072808	A1	20040415	US 2003-678828	20031003
PRAI	US 2001-291488P	P	20010516		
	US 2002-147366	A1	20020516		
	WO 2002-US15690	W	20020516		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002092102	ICM	A61K031-565
	ICS	A61K031-57; A61P015-12
US 2003004145	ECLA	A61K031/566; A61K031/566+M; A61K031/569; A61K031/569+M; A61K031/57; A61K031/57+M; A61K045/06
US 2004072808	ECLA	A61K031/566; A61K031/566+M; A61K031/569; A61K031/569+M; A61K031/57; A61K031/57+M; A61K045/06

AB A method of treating vasomotor symptoms associated with hormone deficiencies is claimed comprising: administering a dose of a therapeutic amount of an estrogenic compound to a subject; administering a dose of a therapeutic amount of a progestin agent to a subject; and administering a second dose of a therapeutic amount of a progestin agent at a later time period to the subject, said second dose comprising a lower dosage of said therapeutic amount of a progestin agent than said first dose. The method further comprises administering an androgen compound in a daily dose. The method can be used for treating hormonal deficiencies, including **menopause.** Also claimed is a method of preventing endometrial hyperplasia associated with estrogen therapy in a subject, said method comprising: administering continuously and uninterruptedly for a first predetd. time period a first dose of a progestin agent to said subject; and administering continuously and uninterruptedly for a second predetd. time period a second dose of a progestin agent to said subject.

ST hormone deficiency condition treatment progestin estrogen androgen
IT Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated, estrogen; treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)
IT Hyperplasia
(endometrial; method of preventing endometrial hyperplasia associated with

estrogen therapy by administration of progestins)
IT Uterus, disease
(endometrium, hyperplasia; method of preventing endometrial hyperplasia associated with estrogen therapy by administration of progestins)
IT Androgens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of conditions relating to hormone deficiencies by administration of estrogens, progestins, and androgens)
IT **Hormone replacement therapy**
Human
(treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)
IT Estrogens
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)
IT Hormones, animal, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)
IT Progestogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)
IT **Menopause**
(treatment; treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)
IT Blood vessel, disease
(vasomotor symptoms; treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)
IT **53-39-4, Oxandrolone 53-39-4D,**
Oxandrolone, esters and salts 53-41-8, Androsterone 53-41-8D, Androsterone, esters and salts 53-43-0, Dehydroepiandrosterone 53-43-0D, Dehydroepiandrosterone, esters and salts 58-18-4, Methyl testosterone 58-18-4D, Methyl testosterone, esters and salts 58-22-0, Testosterone 58-22-0D, Testosterone, esters and salts 76-43-7, Fluoxymesterone 76-43-7D, Fluoxymesterone, esters and salts **434-07-1, Oxymetholone 434-07-1D,**
Oxymetholone, esters and salts 514-61-4 514-61-4D, esters and salts 846-46-8 846-46-8D, esters and salts 1474-55-1, Nandrolone benzoate 1474-55-1D, Nandrolone benzoate, esters and salts 1852-53-5 1852-53-5D, esters and salts **10418-03-8, Stanozolol**
10418-03-8D, Stanozolol, esters and salts
17230-88-5, Danazol 17230-88-5D,
Danazol, esters and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(androgen; treatment of conditions relating to hormone deficiencies by administration of estrogens, progestins, and androgens)
IT **50-28-2, 17β -Estradiol,**
biological studies **50-28-2D, 17β -**
Estradiol, mixts., conjugates, and salts **53-16-7,**
Estrone, biological studies **53-16-7D, Estrone,**
mixts., conjugates, and salts 57-63-6, Ethinyl **estradiol**
57-63-6D, Ethinyl **estradiol**, mixts., conjugates, and salts
57-91-0, 17α -Estradiol
57-91-0D, 17α -Estradiol,
mixts., conjugates, and salts **474-86-2, Equilin**
474-86-2D, Equilin, mixts., conjugates, and salts
474-87-3, Δ8,9-Dehydroestrone **474-87-3D,**

Δ8,9-Dehydroestrone, mixts., conjugates, and salts **517-09-9**
, Equilenin **517-09-9D**, Equilenin, mixts., conjugates, and salts
651-55-8, **17α -Dihydroequilin**
651-55-8D, **17α -Dihydroequilin**,
mixts., conjugates, and salts 979-32-8, **Estradiol** valerate
979-32-8D, **Estradiol** valerate, mixts., conjugates, and salts
1423-97-8, **17β -Dihydroequilenin**
1423-97-8D, **17β -Dihydroequilenin**
, mixts., conjugates, and salts **3563-27-7**, **17**
β -Dihydroequilin 3563-27-7D, **17**
β -Dihydroequilin, mixts., conjugates, and salts
6639-99-2, **17α -Dihydroequilenin**
6639-99-2D, **17α -Dihydroequilenin**
, mixts., conjugates, and salts 23392-54-3, 17β-Δ8,9-
Dehydroestradiol 23392-54-3D, 17β-Δ8,9-Dehydroestradiol,
mixts., conjugates, and salts 162707-56-4, 17α-Δ8,9-
Dehydroestradiol 162707-56-4D, 17α-Δ8,9-Dehydroestradiol,
mixts., conjugates, and salts 360792-45-6, 6-Hydroxy-**17**
β -dihydroequilenin 360792-45-6D, 6-Hydroxy-
17β -dihydroequilenin, mixts., conjugates,
and salts 360792-47-8, 6-Hydroxyequilenin 360792-47-8D,
6-Hydroxyequilenin, mixts., conjugates, and salts 360796-54-9,
6-Hydroxy-**17α -dihydroequilenin**
360796-54-9D, 6-Hydroxy-**17α -**
dihydroequilenin, mixts., conjugates, and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(estrogen; treatment of conditions relating to hormone deficiencies by
administration of progestins, estrogens, and androgens)

IT 51-98-9, Norethindrone acetate 52-76-6, Lynestrenol 57-83-0,
Progesterone, biological studies 68-22-4, Norethindrone 68-23-5,
Norethynodrel 71-58-9, Medroxyprogesterone acetate 79-64-1,
Dimethisterone 152-62-5, Dydrogesterone 297-76-7, Ethynodiol diacetate
302-22-7, Chlormadinone acetate 427-51-0, Cyproterone acetate
432-60-0, Allylestrenol 434-03-7, Ethisterone 434-22-0,
19-Nortestosterone 516-55-2, 5α-Pregnan-3β-ol-20-one
566-61-0 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone
caproate 797-63-7, Levonorgestrel 848-21-5, Norgestrienone 977-79-7,
Medrogestone 3000-39-3, Quingestanol acetate 6533-00-2, dl-Norgestrel
35189-28-7, Norgestimate 54024-22-5, Desogestrel 60282-87-3, Gestodene
74513-62-5, Trimegestone 213474-56-7 475472-71-0, 5α-Pregnan-
3β,20β-diol sulfate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(progestin; treatment of conditions relating to hormone deficiencies by
administration of progestins, estrogens, and androgens)

IT **53-39-4**, **Oxandrolone 53-39-4D**,
Oxandrolone, esters and salts **434-07-1**,
Oxymetholone 434-07-1D, **Oxymetholone**, esters
and salts **10418-03-8**, **Stanozolol 10418-03-8D**
, **Stanozolol**, esters and salts **17230-88-5**,
Danazol 17230-88-5D, **Danazol**, esters and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(androgen; treatment of conditions relating to hormone deficiencies by
administration of estrogens, progestins, and androgens)

RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-
4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **50-28-2, 17β -Estradiol,**
biological studies **50-28-2D, 17β -Estradiol**, mixts., conjugates, and salts **53-16-7, Estrone**, biological studies **53-16-7D, Estrone**, mixts., conjugates, and salts **57-91-0, 17α -Estradiol 57-91-0D, 17α -Estradiol**, mixts., conjugates, and salts **474-86-2, Equilin 474-86-2D, Equilin**, mixts., conjugates, and salts **474-87-3**, Δ8,9-Dehydroestrone **474-87-3D**, Δ8,9-Dehydroestrone, mixts., conjugates, and salts **517-09-9**, Equilenin **517-09-9D**, Equilenin, mixts., conjugates, and salts **651-55-8, 17α -Dihydroequilin 651-55-8D, 17α -Dihydroequilin**, mixts., conjugates, and salts **1423-97-8, 17β -Dihydroequilenin 1423-97-8D, 17β -Dihydroequilenin**, mixts., conjugates, and salts **3563-27-7, 17β -Dihydroequilin 3563-27-7D, 17β -Dihydroequilin**, mixts., conjugates, and salts **6639-99-2, 17α -Dihydroequilenin 6639-99-2D, 17α -Dihydroequilenin**, mixts., conjugates, and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen; treatment of conditions relating to hormone deficiencies by administration of progestins, estrogens, and androgens)
RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 53-16-7 HCAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 57-91-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-91-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-86-2 HCAPLUS
CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-86-2 HCAPLUS
CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-87-3 HCAPLUS
CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-87-3 HCAPLUS
CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517-09-9 HCAPLUS
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517-09-9 HCAPLUS
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651-55-8 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651-55-8 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1423-97-8 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1423-97-8 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3563-27-7 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3563-27-7 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6639-99-2 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6639-99-2 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:574935 HCAPLUS
DN 137:120059
ED Entered STN: 02 Aug 2002
TI Method of treating hormonal deficiencies in women undergoing **estrogen replacement therapy**
IN **Leonard, Thomas W.; Waldon, R. Forrest**
PA **Endeavor Pharmaceuticals, USA**
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-565
ICS A61P005-24
CC 2-4 (Mammalian Hormones)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058706	A2	20020801	WO 2001-US51045	20011221 <--
	WO 2002058706	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002151530	A1	20021017	US 2001-29424	20011220 <--
	CA 2431645	AA	20020801	CA 2001-2431645	20011221 <--
	EP 1343509	A2	20030917	EP 2001-989306	20011221 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004520375	T2	20040708	JP 2002-559040	20011221 <--
	US 2003195177	A1	20031016	US 2003-424243	20030429 <--
PRAI	US 2000-258142P	P	20001222 <--		
	US 2001-29424	A3	20011220 <--		
	WO 2001-US51045	W	20011221 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002058706	ICM	A61K031-565
	ICS	A61P005-24
JP 2004520375	FTERM	4C086/AA01; 4C086/AA02; 4C086/DA09; 4C086/DA10; 4C086/DA12; 4C086/DA13; 4C086/MA02; 4C086/MA04; 4C086/MA52; 4C086/NA06; 4C086/NA14; 4C086/ZA16; 4C086/ZA36; 4C086/ZA81; 4C086/ZA97; 4C086/ZC11; 4C086/ZC75 <--

AB The present invention combines the administration of estrogens with the administration of non-aromatizing androgens to treat hormonal deficiencies in women undergoing **estrogen replacement therapy.** The combined estrogen and non-aromatizing androgen therapy has less of a detrimental effect on the **uterus** than traditional **estrogen replacement therapy.** A progestin may also be administered along with the estrogen and the androgen. Pharmaceutical **compns.** are claimed along with the method of treatment.

ST nonaromatizing androgen **estrogen replacement therapy** women

IT Progestogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hormone replacement therapy** in women with an estrogen, a nonaromatizing androgen, and a progestin)

IT **Uterus**
(**hormone replacement therapy** with estrogen and nonaromatizing androgen with a reduced neg. effect on the **uterus**)

IT Drug delivery systems
(method of treating hormonal deficiencies in women by using a drug formulation containing an estrogen and a non-aromatizing androgen)

IT **Hormone replacement therapy**
Human
(method of treating hormonal deficiencies in women undergoing **estrogen replacement therapy** by

administering non-aromatizing androgens)
IT Androgens
Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treating hormonal deficiencies in women undergoing **estrogen replacement therapy** by administering non-aromatizing androgens)
IT **50-28-2**, 17β **-Estradiol**, biological studies **50-28-2D**, 17β - **Estradiol**, mixts., conjugates, and salts **53-16-7**, **Estrone**, biological studies **53-16-7D**, **Estrone**, mixts., conjugates, and salts **53-39-4**, **Oxandrolone** **53-39-4D**, **Oxandrolone**, esters and salts 57-63-6, Ethinyl **estradiol** 57-63-6D, Ethinyl **estradiol**, mixts., conjugates, and salts **57-91-0**, 17 α **-Estradiol 57-91-0D**, 17 α **-Estradiol**, mixts., conjugates, and salts **434-07-1**, **Oxymetholone 434-07-1D**, **Oxymetholone**, esters and salts **474-86-2**, **Equilin** **474-86-2D**, **Equilin**, mixts., conjugates, and salts **474-87-3**, Δ8,9-Dehydroestrone **474-87-3D**, Δ8,9-Dehydroestrone, mixts., conjugates, and salts **517-09-9** , Equilenin **517-09-9D**, Equilenin, mixts., conjugates, and salts **651-55-8**, 17α **-Dihydroequilin** **651-55-8D**, 17α **-Dihydroequilin**, mixts., conjugates, and salts 979-32-8, **Estradiol** valerate 979-32-8D, **Estradiol** valerate, mixts., conjugates, and salts **1423-97-8**, 17β **-Dihydroequilenin** **1423-97-8D**, 17β **-Dihydroequilenin** , mixts., conjugates, and salts **3563-27-7**, 17 β **-Dihydroequilin 3563-27-7D**, 17 β **-Dihydroequilin**, mixts., conjugates, and salts **6639-99-2**, 17α **-Dihydroequilenin** **6639-99-2D**, 17α **-Dihydroequilenin** , mixts., conjugates, and salts **10418-03-8**, **Stanozolol** **10418-03-8D**, **Stanozolol**, esters and salts **17230-88-5**, **Danazol 17230-88-5D**, **Danazol**, esters and salts 23392-54-3, 17β-Δ8,9-Dehydroestradiol 23392-54-3D, 17β-Δ8,9-Dehydroestradiol, mixts., conjugates, and salts 162707-56-4, 17α-Δ8,9-Dehydroestradiol 162707-56-4D, 17α-Δ8,9-Dehydroestradiol, mixts., conjugates, and salts 360792-45-6, 6-Hydroxy-**17** β **-Dihydroequilenin** 360792-45-6D, mixts., conjugates, and salts 360792-47-8, 6-Hydroxyequilenin 360792-47-8D, 6-Hydroxyequilenin, mixts., conjugates, and salts 360796-54-9, 6-Hydroxy-**17**α **-dihydroequilenin** 360796-54-9D, mixts., conjugates, and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treating hormonal deficiencies in women undergoing **estrogen replacement therapy** by administering non-aromatizing androgens)
IT **50-28-2**, 17β **-Estradiol**, biological studies **50-28-2D**, 17β - **Estradiol**, mixts., conjugates, and salts **53-16-7**, **Estrone**, biological studies **53-16-7D**, **Estrone**, mixts., conjugates, and salts **53-39-4**, **Oxandrolone** **53-39-4D**, **Oxandrolone**, esters and salts **57-91-0** , 17α **-Estradiol 57-91-0D**, 17α **-Estradiol**, mixts., conjugates, and salts **434-07-1**, **Oxymetholone 434-07-1D**, **Oxymetholone**, esters and salts **474-86-2**, **Equilin**

474-86-2D, Equilin, mixts., conjugates, and salts
474-87-3, Δ8,9-Dehydroestrone **474-87-3D**,
Δ8,9-Dehydroestrone, mixts., conjugates, and salts **517-09-9**
, Equilenin **517-09-9D**, Equilenin, mixts., conjugates, and salts
651-55-8, 17α **-Dihydroequilin**
651-55-8D, 17α **-Dihydroequilin**,
mixts., conjugates, and salts **1423-97-8**, **17**
β **-Dihydroequilenin 1423-97-8D**, **17**
β **-Dihydroequilenin**, mixts., conjugates, and salts
3563-27-7, 17β **-Dihydroequilin**
3563-27-7D, 17β **-Dihydroequilin**,
mixts., conjugates, and salts **6639-99-2**, **17**
α **-Dihydroequilenin 6639-99-2D**,
17α **-Dihydroequilenin**, mixts.,
conjugates, and salts **10418-03-8**, **Stanozolol**
10418-03-8D, **Stanozolol**, esters and salts
17230-88-5, **Danazol 17230-88-5D**,
Danazol, esters and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treating hormonal deficiencies in women undergoing **estrogen replacement therapy** by administering non-aromatizing androgens)

RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 53-16-7 HCAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-91-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-91-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 474-86-2 HCAPLUS
CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-86-2 HCAPLUS
CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-87-3 HCAPLUS
CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-87-3 HCAPLUS
CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517-09-9 HCAPLUS
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517-09-9 HCAPLUS
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651-55-8 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651-55-8 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1423-97-8 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1423-97-8 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3563-27-7 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3563-27-7 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6639-99-2 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6639-99-2 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:504629 HCAPLUS
DN 137:83634
ED Entered STN: 05 Jul 2002
TI Estrogen, androgen and vasodilator **compositions** for the treatment of female sexual dysfunction
IN **Leonard, Thomas W.**; Waldon, R. Waldon
PA **Endeavor Pharmaceuticals, USA**
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-565
ICS A61P015-12
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 2
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002051420	A2	20020704	WO 2001-US49978	20011221 <--
	WO 2002051420	A3	20021227		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HŘ, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002107230	A1	20020808	US 2001-29423	20011220 <--
	CA 2431834	AA	20020704	CA 2001-2431834	20011221 <--
	EP 1359920	A2	20031112	EP 2001-992297	20011221 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004520320	T2	20040708	JP 2002-552564	20011221 <--
	US 2004259817	A1	20041223	US 2004-898104	20040723 <--
PRAI	US 2000-257745P	P	20001222 <--		
	US 2001-29423	A1	20011220		
	WO 2001-US49978	W	20011221		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002051420	ICM	A61K031-565
	ICS	A61P015-12
US 2002107230	ECLA	A61K031/56+M; A61K031/565; A61K031/565+M; A61K031/57+M; A61K045/06 <--
JP 2004520320	FTERM	4C084/AA02; 4C084/AA03; 4C084/AA22; 4C084/AA27;

4C084/NA05; 4C084/NA14; 4C084/ZA811; 4C086/AA01;
4C086/BC27; 4C086/BC38; 4C086/DA08; 4C086/DA09;
4C086/DA10; 4C086/DA12; 4C086/DA13; 4C086/MA03;
4C086/MA04; 4C086/MA28; 4C086/MA31; 4C086/MA32;
4C086/MA35; 4C086/MA52; 4C086/MA56; 4C086/MA63;
4C086/NA05; 4C086/NA14; 4C086/ZA81 <--
US 2004259817 ECLA A61K031/56+M; A61K031/565; A61K031/565+M; A61K031/57+M;
A61K045/06 <--

AB A pharmaceutical **composition** for the treatment of sexual dysfunction, particularly post-**menopausal** females, is provided. The **composition** includes a therapeutically effective amount of an estrogenic compound, androgenic compound, vasodilation compound, and a pharmaceutically acceptable carrier. Tablets were prepared containing and estrogen such as **estradiol**, an androgen such as methyltestosterone and a vasodilator such as phentolamine and excipients.

ST estrogen androgen vasodilator **compn** female sexual dysfunction

IT **Sexual behavior**
(disorder, female; estrogen, androgen and vasodilator **compns.** for the treatment of female sexual dysfunction)

IT Vasodilators
(estrogen, androgen and vasodilator **compns.** for the treatment of female sexual dysfunction)

IT Androgens
Estrogens
Progestogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen, androgen and vasodilator **compns.** for the treatment of female sexual dysfunction)

IT Drug delivery systems
(tablets; estrogen, androgen and vasodilator **compns.** for the treatment of female sexual dysfunction)

IT Drug delivery systems
(topical; estrogen, androgen and vasodilator **compns.** for the treatment of female sexual dysfunction)

IT Drug delivery systems
(**vaginal**; estrogen, androgen and vasodilator **compns** . for the treatment of female sexual dysfunction)

IT Adrenoceptor antagonists
(α-; estrogen, androgen and vasodilator **compns.** for the treatment of female sexual dysfunction)

IT **50-28-2**, **17β -Estradiol**,
biological studies 51-98-9, Norethindrone acetate 52-76-6, Lynestrenol **53-16-7**, **Estrone**, biological studies **53-39-4**, **Oxandrolone** 53-41-8, Androsterone 53-43-0, Dehydroepiandrosterone 57-63-6, Ethinylestradiol **57-91-0**, **17α -Estradiol** 58-00-4, Apomorphine 58-18-4, Methyltestosterone 58-19-5, Dromostanolone 58-22-0, Testosterone 62-90-8, Nandrolone phenylpropionate 63-05-8, Androstenedione 65-28-1, Phentolamine mesylate 68-22-4, Norethindrone 68-23-5, Norethynodrel 71-58-9, Medroxyprogesterone acetate 73-05-2, Phentolamine hydrochloride 76-43-7, Fluoxymesterone 79-64-1, Dimethisterone 152-62-5, Dydrogesterone 297-76-7, Ethynodiol diacetate 302-22-7, Chlormadinone acetate 302-23-8, Hydroxyprogesterone acetate 360-70-3, Nandrolone decanoate 427-51-0, Cyproterone acetate 432-60-0, Allylestrenol 434-03-7, Ethisterone **434-07-1**, **Oxymetholone** 434-22-0, 19-Nortestosterone **474-86-2**, **Equilin 474-87-3**, Δ8,9-Dehydroestrone 514-61-4, 17α-Methyl-19-nortestosterone 516-55-2, 5α-Pregnan-3β-ol-20-one **517-09-9**, Equilenin 520-85-4, Medroxyprogesterone 521-12-0, Dromostanolone propionate 521-17-5, Androstenediol 521-18-6, 4-Dihydrotestosterone 566-61-0 566-65-4 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone caproate **651-55-8**, **17 α -Dihydroequilin** 797-63-7, Levonorgestrel

848-21-5, Norgestrienone 912-57-2, Nandrolone cyclohexanepropionate
965-90-2, Ethylestrenol 968-93-4, Testolactone 977-79-7, Medrogestone
979-32-8, **Estradiol** valerate 1099-87-2, Sodium
dehydroepiandrosterone sulfate 1164-95-0, Androsterone acetate
1323-54-2, Acetoxypregnenolone **1423-97-8, 17**
β -**Dihydroequilenin** 1474-55-1, Nandrolone benzoate
2098-66-0, Cyproterone 2529-45-5, Flurogestone acetate 2919-66-6,
Melengestrol acetate 3000-39-3, Quingestanol acetate 3137-73-3,
Anagestone acetate 3562-63-8, Megestrol **3563-27-7, 17**
β -**Dihydroequilin** 5721-91-5, Testosterone
decanoate 5953-68-4, Androsterone propionate 5953-69-5, Androsterone
benzoate 6533-00-2, Norgestrel **6639-99-2, 17**
α -**Dihydroequilenin** 7642-64-0, Nandrolone
furylpropionate **10418-03-8, Stanozolol** 14291-86-2
18470-94-5, Nandrolone cyclohexanecarboxylate 23392-54-3,
17β-Δ8,9-Dehydroestradiol 32717-60-5 35189-28-7,
Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel
58652-20-3, Nomegestrol acetate 60282-87-3, Gestodene 74513-62-5,
Trimegestone 103062-96-0 162707-56-4, 17α-Δ8,9-
Dehydroestradiol 213474-56-7 360792-45-6 360792-47-8,
6-Hydroxyequilenin 360796-54-9 439928-64-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen, androgen and vasodilator **compns.** for the treatment
of female sexual dysfunction)

IT **50-28-2, 17β -Estradiol,**
biological studies **53-16-7, Estrone,** biological
studies **53-39-4, Oxandrolone 57-91-0,**
17α -Estradiol 434-07-1,
Oxymetholone 474-86-2, Equilin
474-87-3, Δ8,9-Dehydroestrone **517-09-9,** Equilenin
651-55-8, 17α -Dihydroequilin
1423-97-8, 17β -Dihydroequilenin
3563-27-7, 17β -Dihydroequilin
6639-99-2, 17α -Dihydroequilenin
10418-03-8, Stanozolol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen, androgen and vasodilator **compns.** for the treatment
of female sexual dysfunction)

RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-91-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 474-86-2 HCAPLUS
CN Estra-1,3,5(10),7-tetraen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474-87-3 HCAPLUS
CN Estra-1,3,5(10),8-tetraen-17-one, 3-hydroxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 517-09-9 HCAPLUS
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651-55-8 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1423-97-8 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3563-27-7 HCAPLUS
CN Estra-1,3,5(10),7-tetraene-3,17-diol, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6639-99-2 HCAPLUS
CN Estra-1,3,5,7,9-pentaene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2002:353298** HCAPLUS
DN **136:350812**
ED Entered STN: 12 May 2002
TI GnRH analogues for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs
IN Arnold, Susi; Reichler, Iris; Hubler, Madeleine
PA University of Zurich, Switz.
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K038-09
ICS A61K045-06; A61P015-12; A61P013-00
CC 2-5 (Mammalian Hormones)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002036144	A1	20020510	WO 2001-CH636	20011026 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2427731	AA	20020510	CA 2001-2427731	20011026	<--
AU 2001095359	A5	20020515	AU 2001-95359	20011026	<--
EP 1330257	A1	20030730	EP 2001-975948	20011026	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001015067	A	20040406	BR 2001-15067	20011026	<--
JP 2004512369	T2	20040422	JP 2002-538955	20011026	<--
US 2004023878	A1	20040205	US 2003-415519	20030430	
PRAI EP 2000-811011	A	20001030	<--		
WO 2001-CH636	W	20011026			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002036144	ICM	A61K038-09
	ICS	A61K045-06; A61P015-12; A61P013-00
JP 2004512369	FTERM	4C076/AA01; 4C076/AA03; 4C076/AA93; 4C076/BB01; 4C076/BB25; 4C076/BB29; 4C076/BB30; 4C076/BB31; 4C076/CC17; 4C084/AA02; 4C084/AA17; 4C084/BA01; 4C084/BA09; 4C084/BA17; 4C084/BA23; 4C084/CA59; 4C084/MA12; 4C084/MA31; 4C084/MA52; 4C084/MA55; 4C084/MA56; 4C084/MA59; 4C084/MA60; 4C084/MA63; 4C084/NA14; 4C084/ZA811 <--
US 2004023878	ECLA	A61K038/09; A61K045/06

AB The use of at least one GnRH analog for the preparation of a medicament for the prevention and/or treatment of side effects of ovariectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and skin/hair changes are disclosed. The GnRH analog is selected from the group consisting of deslorelin acetate, goserelin acetate, nafarelin acetate, buserelin acetate, triptorelin acetate, gonadorelin acetate, leuprolid acetate, danazolum, Cetrorelix or mixts. thereof. The medicament can further comprise another active substance selected from the group consisting of an estrogenic agent, a partial estrogenic agent, a progestational agent, or mixts. thereof. The addnl. active ingredient can also be an α-adrenergic agonist, a β-adrenergic receptor blocking agent, a cholinergic receptor blocking compound, a cholinergic receptor stimulating drug, a smooth muscle relaxant, a nitric oxide synthase substrate, a nitric oxide donor, or mixts. thereof.

ST GnRH analog treatment ovariectomy **menopause** symptom treatment

IT Canis familiaris
Human
Ovariectomy
(GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Cholinergic agonists
Cholinergic antagonists
(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Estrogens
Progestogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Behavior

(aggressive; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Fur
Hair
Skin
(changes; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Mental disorder
(depression; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT **Menopause**
(**disorder, hot flash**; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT **Menopause**
(**disorder**, vasomotor symptoms; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Bladder, disease
(incontinence; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(intravaginal; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Emotion
(mood changes; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(nasal; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(oral; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(parenterals; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT **Menopause**
(**postmenopause**; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT **Menopause**
(**premenopause**; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(rectal; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

IT Drug delivery systems
(s.c. implant; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
IT Drug delivery systems
(s.c.; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
IT Drug delivery systems
(slow-release; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
IT Muscle relaxants
(smooth; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
IT Drug delivery systems
(transdermal; GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
IT Adrenoceptor agonists
(α-; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
IT Adrenoceptor antagonists
(β-; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
IT 9034-40-6D, GnRH, analogs **17230-88-5**, Danazolum 34973-08-5, Gonadorelin acetate 68630-75-1, Buserelin acetate 74381-53-6, Leuprolide acetate 76932-60-0, Nafarelin acetate 82318-06-7, Deslorelin acetate 120287-85-6, Cetrorelix 145781-92-6, Goserelin acetate 160296-12-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
IT 50-27-1, Estriol **50-28-2**, 17β - **Estradiol**, biological studies **53-16-7**, **Estrone**, biological studies 57-83-0, Progesterone, biological studies 68-22-4, Norethisterone 68-96-2, Hydroxyprogesterone 520-85-4, Medroxyprogesterone 797-63-7, Levonorgestrel 979-32-8, **Estradiol** valerate 6533-00-2, Norgestrel 10540-29-1, Tamoxifen 31477-60-8, Centchroman 60282-87-3, Gestodene 67392-87-4, Drospirenone 84449-90-1, Raloxifene 89778-26-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
IT 10102-43-9, Nitric oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(donors; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
IT 125978-95-2, Nitric oxide synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(substrates; GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Conn, P; NEW ENGLAND JOURNAL OF MEDICINE 1991, V324, P93 HCAPLUS
(2) Janssens, L; VETERINARY RECORD 1997, V141(24), P620 MEDLINE
(3) Praecis Pharm Inc; WO 9955358 A 1999 HCAPLUS

IT **17230-88-5**, Danazolum
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH analogs for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **50-28-2**, **17β -Estradiol**,
biological studies **53-16-7**, **Estrone**, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L60 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2000:900464** HCAPLUS
DN **134:37563**
ED Entered STN: 22 Dec 2000
TI Administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or those receiving estrogen supplementation
IN Rosario-jansen, Theresa; Mazer, Norman A.
PA Watson Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-56
CC 2-4 (Mammalian Hormones)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000076522	A1	20001221	WO 2000-US15834	20000609 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2376797	AA	20001221	CA 2000-2376797	20000609 <--
	EP 1189619	A1	20020327	EP 2000-939710	20000609 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000011740	A	20020514	BR 2000-11740	20000609 <--
	TR 200200406	T2	20020621	TR 2002-200200406	20000609 <--
	JP 2003505345	T2	20030212	JP 2001-502855	20000609 <--
	US 6583129	B1	20030624	US 2000-591141	20000609 <--
	NZ 516502	A	20040326	NZ 2000-516502	20000609 <--
	AU 775145	B2	20040722	AU 2000-54758	20000609 <--
	RU 2234920	C2	20040827	RU 2002-100356	20000609 <--
	NO 2001006046	A	20020206	NO 2001-6046	20011211 <--
	ZA 2001010181	A	20021211	ZA 2001-10181	20011211 <--
	US 2003153540	A1	20030814	US 2002-278033	20021022 <--
PRAI	US 1999-138851P	P	19990611	<--	
	US 1999-138854P	P	19990611	<--	
	US 1999-139323P	P	19990611	<--	
	US 2000-591141	A1	20000609	<--	
	WO 2000-US15834	W	20000609	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES

WO 2000076522 ICM A61K031-56

AB The present invention provides **compns.**, methods, and kits for improving health in a woman having elevated sex hormone binding globulin (SHBG) levels, or who is receiving oral estrogen supplementation, by non-orally administering an effective amount of an androgenic steroid. Further, the present invention provides **compns.**, methods and kits for coadministering an effective amount of an orally administered estrogen and an effective amount of a non-orally administered androgenic steroid for women in need of estrogen supplementation. For example, a transdermal testosterone patch (300 mcg/day nominal delivery) can be used in patients concomitantly receiving transdermal **estradiol** or oral conjugated equine estrogens. Progestin may also be administered along with estrogen and androgen in order to provide endometrial safety or effective contraception. Improvement in the health of the woman, is manifested by restoration, enhancement, or improvement of sexual activity, vital energy, sense of wellbeing, mood and sense of emotional well being, shyness, cognitive abilities, muscle mass and function, body **compn** ., bone mineral d., skin and hair condition, pubic hair, urogenital atrophy, **vaginal** dryness, dry eyes, health in autoimmune conditions, vasomotor instability, breast tenderness, and symptoms of premenstrual syndrome.

ST androgen estrogen administration women improved health

IT Estrogen receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SERMs (selective estrogen receptor modulators); administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Globulins, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(SHBG (sex hormone-binding globulin); administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT **Hormone replacement therapy**
Menopause
(administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Androgens
Estrogens
Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Urogenital tract
(atrophy, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Mineral elements, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(bone, d., improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Hair
Skin
(condition, improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Estrogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(conjugated; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Eye, disease
(dry, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT **Vagina**
(dryness, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Autoimmune disease
(health in, improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Estrogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy, esters; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Energy metabolism, animal
(improved energy; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Cognition
Sexual behavior
(improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Muscle
(mass, improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Bone
(minerals, d., improved; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Estrogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phytoestrogens; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT **Menopause**
(**postmenopause**; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Ovarian cycle
(premenstrual syndrome, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Mammary gland
(tenderness, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Circulation
(vasomotor instability, improvement; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)

IT Emotion
(well being; administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)
IT 57-83-0, Progestin, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen and progestin supplementation)
IT **50-28-2, 17β -Estradiol,**
biological studies 52-78-8, Norethandrolone **53-16-7,**
Estrone, biological studies **53-39-4, Oxandrolone**
53-41-8, Androsterone 53-43-0, Dehydroepiandrosterone 57-63-6, Ethinyl **estradiol** 57-85-2, Testosterone propionate **57-91-0,**
17α -Estradiol 58-18-4,
Methyltestosterone 58-20-8, Testosterone cypionate 58-22-0,
Testosterone 63-05-8, Androstenedione 71-58-9, Medroxyprogesterone acetate 72-63-9, Methandrostenolone 76-43-7, Fluoxymesterone 145-13-1, Pregnenolone 315-37-7, Testosterone enanthate 382-45-6, Adrenosterone **434-07-1, Oxymetholone** 434-22-0,
Nandrolone 438-67-5, Sodium **estrone** sulfate 514-61-4
521-18-6, Dihydrotestosterone 965-90-2, Ethylestrenol 968-93-4,
Testolactone 1045-69-8, Testosterone acetate 1424-00-6, Mesterolone 1605-89-6, Bolasterone 5704-03-0, Testosterone phenylacetate 5721-91-5, Testosterone decanoate **10418-03-8, Stanozolol** 15262-86-9, Testosterone isocaproate **17230-88-5, Danazol** 105165-22-8, Testosterone buciclate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Chein, E; US 5855920 A 1999 HCAPLUS
(2) Hughes; US 5962021 A 1999 HCAPLUS
(3) Labrie, F; US 5550107 A 1996 HCAPLUS
IT **50-28-2, 17β -Estradiol,**
biological studies **53-16-7, Estrone**, biological studies **53-39-4, Oxandrolone 57-91-0,**
17α -Estradiol 434-07-1,
Oxymetholone 10418-03-8, Stanozolol
17230-88-5, Danazol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(administration of non-oral androgenic steroids to improve health in women with elevated SHBG levels or receiving estrogen supplementation)
RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-91-0 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2000:475529** HCAPLUS
DN **133:94499**
ED Entered STN: 14 Jul 2000
TI Hormone replacement for breast cancer patients
IN Hughes, Claude L, Jr.
PA Cedars-Sinai Medical Center, USA
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-00
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 2
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000040230	A2	20000713	WO 2000-US96	20000104 <--
WO 2000040230	A3	20010517		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-226068 A 19990106 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000040230	ICM	A61K031-00

AB Disclosed is a method of androgen replacement therapy to maintain or restore a woman's physiol. normality, including her bone d., vasomoter stability, sexual function, and energy. Also described is a method of treating or preventing osteoporosis in women. A woman is administered pharmaceutical **compns.**, comprising a non-aromatizable androgen, without **estradiol** or any estrogenic compound, by a route other than the digestive tract, such that 5 to 500 μg of the non-aromatizable androgen is administered daily. Pharmaceutical **compns.** for delivering a non-aromatizable androgen to a woman at higher than normal risk of breast cancer or endometrial cancer, are formulated to deliver an ED transdermally, transmucosally or by any delivery route, except the digestive tract. Non-aromatizable androgens that are contemplated include, but are not limited to, methyltestosterone, 17-alpha-methyl-19-nor-testosterone, **danazol**, fluoxymesterone, methandrostenolone, **oxandrolone**, **oxymetholone**, **stanozolol**, and testolactone. But also contemplated among useful non-aromatizable

androgens are androgenic progestins, including desogestrel, norgestimate, norethindrone, norethinedrone acetate, norgestrel, ethynodiol diacetate and levonorgestrel. The absence from these **compns.** of **estradiol**, or any estrogenic compound, such as testosterone, avoids the estrogen exposure which increases the cancer risk. Androgen delivery other than by ingestion permits lower EDs and thus lowers the risk of virilizing effects and potential liver toxicity than previously available androgen replacement prepns.

ST androgen replacement therapy breast cancer

IT Drug delivery systems
(adhesive patches; non-aromatizable androgen replacement for breast cancer patients)

IT Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(androgenic; non-aromatizable androgen replacement for breast cancer patients)

IT **Uterus**, neoplasm
Uterus, neoplasm
(endometrium, inhibitors; non-aromatizable androgen replacement for breast cancer patients)

IT Antitumor agents
Uterus, neoplasm
(endometrium; non-aromatizable androgen replacement for breast cancer patients)

IT Estrogens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(exclusion of; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
(gels; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
(implants; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
(injections; non-aromatizable androgen replacement for breast cancer patients)

IT Antitumor agents
(mammary gland; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
(mucosal; non-aromatizable androgen replacement for breast cancer patients)

IT Mammary gland
Mammary gland
(neoplasm, inhibitors; non-aromatizable androgen replacement for breast cancer patients)

IT Mammary gland
(neoplasm; non-aromatizable androgen replacement for breast cancer patients)

IT Osteoporosis
(non-aromatizable androgen replacement for breast cancer patients)

IT Androgens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems
(ointments, creams; non-aromatizable androgen replacement for breast cancer patients)

IT Drug delivery systems

(oral; non-aromatizable androgen replacement for breast cancer patients)
IT Osteoporosis
(therapeutic agents; non-aromatizable androgen replacement for breast cancer patients)
IT Drug delivery systems
(transdermal; non-aromatizable androgen replacement for breast cancer patients)
IT Drug delivery systems
(**vaginal**; non-aromatizable androgen replacement for breast cancer patients)
IT **50-28-2**, **Estradiol**, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(exclusion of; non-aromatizable androgen replacement for breast cancer patients)
IT 51-98-9, Norethindrone acetate **53-39-4**, **Oxandrolone**
58-18-4, Methyltestosterone 68-22-4, Norethindrone 72-63-9, Methandrostenolone 76-43-7, Fluoxymesterone 297-76-7, Ethynodiol diacetate **434-07-1**, **Oxymetholone** 514-61-4, 17α-Methyl-19-nor-testosterone 521-18-6, 5α-Dihydrotestosterone 797-63-7, Levonorgestrel 968-93-4, Testolactone 6533-00-2, Norgestrel **10418-03-8**, **Stanozolol** **17230-88-5**, **Danazol** 35189-28-7, Norgestimate 54024-22-5, Desogestrel
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(non-aromatizable androgen replacement for breast cancer patients)
IT **50-28-2**, **Estradiol**, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(exclusion of; non-aromatizable androgen replacement for breast cancer patients)
RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **53-39-4**, **Oxandrolone** **434-07-1**, **Oxymetholone** **10418-03-8**, **Stanozolol** **17230-88-5**, **Danazol**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(non-aromatizable androgen replacement for breast cancer patients)
RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **2000:116900** HCAPLUS
DN **132:156868**
ED Entered STN: 18 Feb 2000
TI Use of a NK-1 receptor antagonist for treating or preventing abnormal bone resorption
IN Hargreaves, Richard John; Rupniak, Nadia Melanie
PA Merck Sharp & Dohme Limited, UK
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-5377
ICS A61K031-675; A61K031-5375; A61K031-438; A61K031-4545; A61K031-454; A61K031-451; A61K031-4035; A61K031-404; A61K031-4709; A61K031-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 2
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000007598	A1	20000217	WO 1999-GB2509	19990730 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2339146	AA	20000217	CA 1999-2339146	19990730 <--
	AU 9950599	A1	20000228	AU 1999-50599	19990730 <--
	AU 763615	B2	20030731		
	EP 1102590	A1	20010530	EP 1999-934993	19990730 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002522389	T2	20020723	JP 2000-563283	19990730 <--
PRAI	GB 1998-16897	A	19980804 <--		
	WO 1999-GB2509	W	19990730 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000007598	ICM	A61K031-5377
	ICS	A61K031-675; A61K031-5375; A61K031-438; A61K031-4545; A61K031-454; A61K031-451; A61K031-4035; A61K031-404; A61K031-4709; A61K031-00
WO 2000007598	ECLA	A61K031/00+A; A61K031/4035; A61K031/404; A61K031/438; A61K031/451; A61K031/454; A61K031/4545; A61K003/4709; A61K031/5375; A61K031/5377; A61K031/675 <--

OS MARPAT 132:156868

AB The present invention relates to the use of NK-1 receptor antagonist **compns.** for the treatment or prevention of abnormal bone resorption, optionally in combination with 1 or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones. Thus, tablets contained NK-1 receptor antagonist 50.0, microcryst. cellulose 80.0, modified food corn starch 80.0, lactose 189.5, and Mg stearate 0.5 mg/tablet.

ST NK1 receptor antagonist abnormal bone resorption; estrogen receptor bone resorption pharmaceutical; bisphosphonate bone resorption pharmaceutical

IT Osteoporosis
(NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Estrogens
Progestogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Tachykinin receptors
(NK1 antagonists; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Bone, disease
(Paget's; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Bone
(demineralization; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Periodontium
(disease; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hormones; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Androgen receptors
Estrogen receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulators; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Bone, disease
(osteolysis, periprosthetic; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Hormones, animal, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Osteoporosis
(**postmenopausal**; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Bone
(resorption; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Drug delivery systems
(tablets; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT Osteoporosis
(therapeutic agents; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT **50-28-2**, **Estradiol**, biological studies 52-78-8, Norethandrolone **53-39-4**, **Oxandrolone** 53-43-0, Dehydroepiandrosterone 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-22-0, Testosterone 63-05-8, Androstenedione

68-22-4, Norethisterone 72-63-9, Methandrostenolone 76-43-7, Fluoxymesterone 315-37-7, Testosterone enanthate 360-70-3, Nandrolone decanoate **434-07-1**, **Oxymetholone** 434-22-0, 19-Nortestosterone 521-17-5, Androstenediol 521-18-6, 5α-Dihydrotestosterone 968-49-0 977-35-5, Epiandrosterone sulfate 1845-11-0, Nafoxidine 2809-21-4 5591-27-5, Clometherone 9007-12-9, Calcitonin **10418-03-8**, **Stanozolol** 10448-84-7, Nitromifene 10540-29-1, Tamoxifen 10596-23-3 15262-77-8, Delmadinone **17230-88-5**, **Danazol** 31477-60-8, Ormeloxifene 40391-99-9 63619-84-1, Trioxifene 66376-36-1, Alendronate 75755-07-6, Piridronate 82413-20-5, Droloxifene 84449-90-1, Raloxifene 89778-26-7, Toremifene 105462-24-6 114084-78-5, Ibandronate 116057-75-1, Idoxifene 118072-93-8, Zoledronate 121268-17-5 124351-85-5, Cimadronate 147764-85-0, BE-25327 172673-17-5 172673-18-6 172673-19-7 172673-20-0 172673-21-1 172673-22-2 172822-01-4 175737-59-4 190791-29-8, CP-336156 200953-48-6 200954-82-1 200954-85-4 200954-87-6 200955-96-0 200955-98-2 200957-56-8 200957-59-1 200957-88-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hypercalcemia; NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Chole, R; AMERICAN JOURNAL OF OTOLOGY 1998, V19(4), P521 MEDLINE
(2) Ciba Geigy Ag; EP 0532456 A 1993 HCAPLUS
(3) Donald, G; WO 9843639 A 1998 HCAPLUS
(4) Fujisawa Pharmaceutical; EP 0443132 A 1991 HCAPLUS
(5) Glaxo Group Ltd; WO 9508549 A 1995 HCAPLUS
(6) Goto, T; CELL AND TISSUE RESEARCH 1998, V293(1), P87 HCAPLUS
(7) Lilly Co Eli; WO 9514017 A 1995 HCAPLUS
(8) Lilly Co Eli; EP 0693489 A 1996 HCAPLUS
(9) Lilly Co Eli; EP 0761219 A 1997 HCAPLUS
(10) MI, Y; WO 9637207 A 1996 HCAPLUS
(11) Maccoss, M; WO 9523798 A 1995 HCAPLUS
(12) Matthew, E; WO 9749710 A 1997 HCAPLUS
(13) Merck & Co Inc; EP 0577394 A 1994 HCAPLUS
(14) Merck Sharp & Dohme; WO 9518124 A 1995 HCAPLUS
(15) Pfizer; EP 0436334 A 1991 HCAPLUS
(16) Pfizer; WO 9217449 A 1992 HCAPLUS
(17) Rhone Poulenc Rorer Sa; WO 9321155 A 1993 HCAPLUS
(18) Rhone Poulenc Rorer Sa; WO 9416697 A 1994 HCAPLUS
(19) Rhone Poulenc Rorer Sa; WO 9422822 A 1994 HCAPLUS
(20) Sanofi Elf; EP 0591040 A 1994 HCAPLUS

IT **50-28-2**, **Estradiol**, biological studies **53-39-4**, **Oxandrolone 434-07-1**, **Oxymetholone 10418-03-8**, **Stanozolol 17230-88-5**, **Danazol**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK-1 receptor antagonist for treatment of or prevention of abnormal bone resorption)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **1998:87617** HCAPLUS
DN **128:149982**
ED Entered STN: 14 Feb 1998
TI Use of sex steroid function modulators to treat wounds and fibrotic disorders
IN Ferguson, Mark William James; Ashcroft, Gillian Sarah
PA Victoria University of Manchester, UK; Ferguson, Mark William James; Ashcroft, Gillian Sarah
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-565
ICS A61K031-57; A61K031-135; A61K031-158; A61K031-105; A61K031-166; A61K031-122
CC 2-4 (Mammalian Hormones)
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9803180	A2	19980129	WO 1997-GB1973	19970722 <--
WO 9803180	A3	19980604		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,

GN, ML, MR, NE, SN, TD, TG

CA 2261263	AA	19980129	CA 1997-2261263	19970722	<--
AU 9736288	A1	19980210	AU 1997-36288	19970722	<--
AU 734465	B2	20010614			
ZA 9706480	A	19990122	ZA 1997-6480	19970722	<--
EP 930876	A2	19990728	EP 1997-932922	19970722	<--
EP 930876	B1	20041020			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2000515523	T2	20001121	JP 1998-506706	19970722	<--
AT 279916	E	20041115	AT 1997-932922	19970722	<--
EP 1506775	A1	20050216	EP 2004-77420	19970722	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
AU 755438	B2	20021212	AU 2001-54179	20010703	<--
US 2002042401	A1	20020411	US 2001-939611	20010828	<--
US 6696433	B2	20040224			
US 2004132701	A1	20040708	US 2003-740525	20031222	<--
PRAI GB 1996-15348	A	19960722	<--		
GB 1997-1600	A	19970127	<--		
WO 1997-GB1973	W	19970722	<--		
EP 1997-932922	A3	19980129	<--		
US 1999-230226	B1	19990421	<--		
US 2001-939611	A1	20010828			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9803180	ICM	A61K031-565
	ICS	A61K031-57; A61K031-135; A61K031-158; A61K031-105; A61K031-166; A61K031-122
WO 9803180	ECLA	A61K031/05; A61K031/565T10; A61K031/565T5; A61K031/57; A61K031/57L; A61K031/57L5L; A61K031/57L5; A61K031/66D10; A61K031/138; A61K031/222; A61K031/565; A61K031/565F; A61K031/565L; A61K031/55L5; A61K031/565T; A61K031/565T10L <--
US 2002042401	ECLA	A61K031/05; A61K031/57L; A61K031/57L5; A61K031/57L5L; A61K031/58; A61K031/66D10; A61K031/138; A61K003/222; A61K031/565; A61K031/565F; A61K031/565L; A61K031/565L5; A61K031/565T; A61K031/565T5; A61K031/65T10; A61K031/565T10L; A61K031/57 <--

AB The present application relates to the use of compds. that influence the sex hormone system for the treatment of wounds and/or fibrotic disorders. Preferred compds. for use in such treatments are steroid hormones and especially the estrogens. **Compns.** containing the compds. of the invention are also claimed.

ST sex steroid function modulators wound healing; fibrosis treatment sex steroid function modulators

IT Drug delivery systems
(aerosols; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Androgen receptors
Estrogen receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(agonists and antagonists; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Progesterone receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(agonists; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Hormones, animal, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anabolic steroids; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Androgens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiandrogens; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Estrogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiestrogens; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiprogestins; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Estrogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems
(gels; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Steroids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hormones; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems
(hydrogels; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems
(implants; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems
(liqs.; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Endocrine system
(modulators; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems
(ointment; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems
(ointments, creams; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Estrogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phytoestrogens; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems

(powder; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Steroids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sex, precursors; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Steroids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sex; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems
(solns., ophthalmic; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Hormones, animal, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(steroid; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Sex hormones
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(steroidal, precursors; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Sex hormones
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(steroidal; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Drug delivery systems
Fibrosis
Wound healing promoters
(use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT Androgens
Estrogens
Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT 9002-61-3, Chorionic gonadotrophin 9002-67-9, LH 9002-68-0, FSH
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulators; use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT 50-27-1, Estriol **50-28-2**, **Estradiol**, biological studies 50-41-9, Clomiphene citrate 53-43-0, DHEA 56-53-1, Stilbestrol 57-63-6, Ethinylestradiol 57-83-0, Progesterone, biological studies 72-33-3, Mestranol 84-17-3, Dienestrol 427-51-0, Cyproterone acetate 434-22-0, Nandrolone 481-97-0, **Estrone** 3-sulfate 566-48-3, Formestane 651-48-9, DHEA sulfate 2624-43-3, Cyclofenil 4719-75-9 5630-53-5, Tibolone 7280-37-7, Piperazine **estrone** sulfate **10418-03-8**, **Stanozolol** 10540-29-1, Tamoxifen 13311-84-7, Flutamide 28014-46-2, Polyestradiol

phosphate 102676-31-3, Fadrozole hydrochloride 107868-30-4, Exemestane 120511-73-1, Anastrozole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT 51-98-9, Norethisterone acetate 57-85-2, Testosterone propionate 58-22-0, Testosterone 58-22-0D, Testosterone, esters 68-22-4, Norethisterone 71-58-9, Medroxyprogesterone acetate 152-62-5, Dydrogesterone 297-76-7, Ethynodiol diacetate 315-37-7, Testosterone enanthate 432-60-0, Allylestrenol 521-18-6, Dihydrotestosterone 571-20-0 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone hexanoate 797-63-7, Levonorgestrel 1253-28-7, Gestronol hexanoate 1424-00-6, Mesterolone 1852-53-5 3836-23-5, Norethisterone enanthate 5949-44-0, Testosterone undecanoate 6533-00-2, Norgestrel 16320-04-0, Gestrinone **17230-88-5**, **Danazol** 35189-28-7, Norgestimate 54024-22-5, Desogestrel 60282-87-3, Gestodene
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(use of sex steroid function modulators to treat wounds and fibrotic disorders)

IT **50-28-2**, **Estradiol**, biological studies
10418-03-8, **Stanozolol**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of sex steroid function modulators to treat wounds and fibrotic disorders)

RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **17230-88-5, Danazol**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(use of sex steroid function modulators to treat wounds and fibrotic disorders)
RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **1994:622993** HCAPLUS
DN **121:222993**
ED Entered STN: 12 Nov 1994
TI Methods and formulations for use in treating oophorectomized women
IN Pike, Malcolm C.; Spicer, Darcy V.
PA University of Southern California, USA
SO U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 952,513.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K009-50
ICS A61K009-14
NCL 424426000
CC 2-4 (Mammalian Hormones)
Section cross-reference(s): 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5340586	A	19940823	US 1993-62886	19930517 <--
	US 5211952	A	19930518	US 1991-684612	19910412 <--
	US 5340584	A	19940823	US 1993-952513	19930201 <--
	CA 2162260	AA	19941124	CA 1994-2162260	19940512 <--
	WO 9426208	A1	19941124	WO 1994-US5262	19940512 <--
	W: CA, FI, NO				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
EP 748191 A1 19961218 EP 1994-917357 19940512 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
NO 9504612 A 19960112 NO 1995-4612 19951115 <--
PRAI US 1991-684612 A2 19910412 <--
US 1993-952513 A2 19930201 <--
WO 1992-US2973 W 19920410 <--
US 1993-62886 A 19930517 <--
WO 1994-US5262 W 19940512 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5340586	ICM	A61K009-50
	ICS	A61K009-14
	NCL	424426000
US 5340586	ECLA	A61K031/565+M; A61K031/57+M; A61K038/09; A61K038/09+M <--
US 5340584	ECLA	A61K038/09; A61K038/09+M <--
WO 9426208	ECLA	A61K009/16H6D4; A61K031/565+M; A61K031/57+M <--

AB **Compns.** and methods which are effective to prevent symptoms of loss of ovarian function (e.g., in oophorectomized women) over a period of time are described, consisting essentially of an effective amount of an estrogenic **composition** and an effective amount of an androgenic **composition** The levels of estrogens and androgens employed are sufficient to reduce bone mineral d. loss and minimize other side effects observed after oophorectomy, and at such low doses as to minimize any adverse impact on the patient's long-term prognosis or (in the case of testosterone) result in addnl. side effects.

ST oophorectomy estrogen androgen combined therapy

IT Ovariectomy
(ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Androgens
Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Ovary, disease
(failure, oophorectomy symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(injections, i.m., ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(injections, s.c., ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(transdermal, ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(**vaginal**, ovarian failure symptoms treatment with estrogen and androgen combinations)

IT 50-27-1, Estriol **50-28-2**, **Estradiol**, biological studies 50-50-0, **Estradiol** benzoate **53-16-7**, **Estrone**, biological studies **53-39-4**, **Oxandrolone** 56-53-1, Diethylstilbestrol 57-63-6, Ethinyl **estradiol** 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-19-5, Dromostanolone 58-20-8, Testosterone cypionate 58-22-0, Testosterone 63-05-8, Androstenedione 72-33-3, Mestranol 152-43-2, Quinestrol 313-06-4, **Estradiol** cypionate 315-37-7, Testosterone enanthate 360-70-3, Nandrolone decanoate **434-07-1**, Oxymethalone 434-22-0, Nandrolone 514-68-1 **517-09-9**, Equilenin 521-10-8, Methandriol 521-18-6, Dihydrotestosterone 965-90-2, Ethylestrenol

968-93-4, Testolactone 979-32-8, **Estradiol** valerate
1240-04-6 7280-37-7, Piperazine **estrone** sulfate
10418-03-8, **Stanozolol** 15183-37-6, Estetrol
17230-88-5, **Danazol** 27651-95-2, Equilenin sulfate
28014-46-2, Polyestradiol phosphate 147827-23-4, Pinestrol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ovarian failure symptoms treatment with estrogen and androgen combinations)

IT **50-28-2**, **Estradiol**, biological studies **53-16-7**
, **Estrone**, biological studies **53-39-4**,
Oxandrolone 434-07-1, Oxymethalone **517-09-9**,
Equilenin **10418-03-8**, **Stanozolol 17230-88-5**,
Danazol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ovarian failure symptoms treatment with estrogen and androgen combinations)

RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 517-09-9 HCAPLUS
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **1994:622992** HCAPLUS
DN **121:222992**
ED Entered STN: 12 Nov 1994
TI Method and formulations for use in treating benign gynecological disorders
IN Pike, Malcolm C.; Spicer, Darcy V.
PA University of Southern California, USA
SO U.S., 10 pp. Cont.-in-part of U.S. Ser. No. 952,513.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61F002-02
ICS A61F006-06; A61K037-38; A61K009-50
NCL 424426000
CC 2-4 (Mammalian Hormones)
Section cross-reference(s): 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5340585	A	19940823	US 1993-62883	19930517	<--
	US 5211952	A	19930518	US 1991-684612	19910412	<--
	CA 2162261	AA	19941124	CA 1994-2162261	19940512	<--
	WO 9426207	A1	19941124	WO 1994-US5222	19940512	<--
	W: CA, FI, NO					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	EP 748190	A1	19961218	EP 1994-917349	19940512	<--
	EP 748190	B1	20030730			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
	AT 245992	E	20030815	AT 1994-917349	19940512	<--
	PT 748190	T	20031231	PT 1994-917349	19940512	<--

	ES 2204917	T3	20040501	ES 1994-917349	19940512 <--
	NO 9504611	A	19960116	NO 1995-4611	19951115 <--
PRAI	US 1991-684612	A2	19910412 <--		
	US 1992-952513	A2	19921203 <--		
	US 1993-62883	A	19930517 <--		
	WO 1994-US5222	W	19940512 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5340585	ICM	A61F002-02
	ICS	A61F006-06; A61K037-38; A61K009-50
	NCL	424426000
US 5340585	ECLA	A61K038/09; A61K038/09+M <--
WO 9426207	ECLA	A61K009/00M8B; A61K009/16H6D4; A61K038/09+M <--

AB **Compns.** and methods which are effective to treat benign gynecol. disorders for extended periods of time in women in whom the risk of endometrial stimulation is minimized or absent are described, wherein an effective amount of a gonadotropin hormone-releasing hormone **compn** . and an effective amount of an estrogenic **composition** are provided over a period of time, optionally with addition of an androgenic **composition** For example, both buserelin and **estradiol** were provided in the form of microspheres prepared from lactide-glycolide copolymer for i.m. administration over a 4 mo duration.

ST gonadotropin releasing hormone estrogen gynecol disorder; buserelin **estradiol** premenstrual syndrome

IT Ovary, neoplasm
(GnRH **composition** and estrogenic **composition** combination for treatment of benign gynecol. disorders)

IT Androgens
Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH **composition** and estrogenic **composition** combination for treatment of benign gynecol. disorders)

IT Ovarian cycle
(disorder, premenstrual syndrome, GnRH **composition** and estrogenic **composition** combination for treatment of benign gynecol. disorders)

IT Pharmaceutical dosage forms
(injections, i.m., GnRH **composition** and estrogenic **compn** . combination for treatment of benign gynecol. disorders)

IT Pharmaceutical dosage forms
(injections, s.c., GnRH **composition** and estrogenic **compn** . combination for treatment of benign gynecol. disorders)

IT Pharmaceutical dosage forms
(transdermal, GnRH **composition** and estrogenic **composition** combination for treatment of benign gynecol. disorders)

IT Pharmaceutical dosage forms
(**vaginal**, GnRH **composition** and estrogenic **compn** . combination for treatment of benign gynecol. disorders)

IT 50-27-1, Estriol **50-28-2**, **Estradiol**, biological studies 50-50-0, **Estradiol** benzoate **53-16-7**, **Estrone**, biological studies **53-39-4**, **Oxandrolone** 56-53-1, Diethylstilbestrol 57-63-6, Ethinyl **estradiol** 57-83-0, Progesterone, biological studies 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-19-5, Dromostanolone 58-20-8, Testosterone cypionate 58-22-0, Testosterone 62-90-8, Nandrolone phenpropionate 63-05-8, Androstenedione 72-33-3, Mestranol 152-43-2, Quinestrol 313-06-4, **Estradiol** cypionate 315-37-7, Testosterone enanthate 360-70-3, Nandrolone decanoate **434-07-1** , Oxymethalone 514-68-1 **517-09-9**, Equilenin 521-10-8, Methandriol 521-18-6, Dihydrotestosterone 965-90-2, Ethylestrenol 968-93-4, Testolactone 979-32-8, **Estradiol** valerate 1240-04-6 7280-37-7, Piperazine **estrone** sulfate 9034-40-6, Gonadotropin releasing hormone **10418-03-8**, **Stanozolol**

15183-37-6, Estetrol **17230-88-5**, **Danazol** 27651-95-2, Equilenin sulfate 28014-46-2, Polyestradiol phosphate 33515-09-2, Gonadorelin 57773-63-4, Decapeptyl 57773-65-6, Deslorelin 57982-77-1, Buserelin 65807-02-5, Goserelin 74381-53-6, Leuprolide acetate 76712-82-8, Histrelin 76932-56-4, Nafarelin 147827-23-4, Pinestrol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH **composition** and estrogenic **composition** combination for treatment of benign gynecol. disorders)

IT **50-28-2**, **Estradiol**, biological studies **53-16-7**, **Estrone**, biological studies **53-39-4**, **Oxandrolone 434-07-1**, Oxymethalone **517-09-9**, Equilenin **10418-03-8**, **Stanozolol 17230-88-5**, **Danazol**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH **composition** and estrogenic **composition** combination for treatment of benign gynecol. disorders)

RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 517-09-9 HCAPLUS
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN
AN **1993:198196** HCAPLUS
DN **118:198196**
ED Entered STN: 14 May 1993
TI Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders
IN Spicer, Darcy Vernon; Pike, Malcolm Cecil
PA University of Southern California, USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-14
ICS A61F002-02
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 2
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9218107	A1	19921029	WO 1992-US2973	19920410 <--
	W: CA, FI, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	US 5211952	A	19930518	US 1991-684612	19910412 <--
	CA 2084891	AA	19921013	CA 1992-2084891	19920410 <--
	CA 2084891	C	19990105		
	EP 538443	A1	19930428	EP 1992-910686	19920410 <--
	EP 538443	B1	19971001		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	AT 158717	E	19971015	AT 1992-910686	19920410 <--
	ES 2109995	T3	19980201	ES 1992-910686	19920410 <--

NO	9204755	A	19930209	NO 1992-4755	19921209 <--
FI	104789	B1	20000414	FI 1992-5652	19921211 <--
US	5340584	A	19940823	US 1993-952513	19930201 <--
PRAI US	1991-684612	A2	19910412 <--		
	WO 1992-US2973	W	19920410 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9218107	ICM	A61K009-14
	ICS	A61F002-02
US 5340584	ECLA	A61K038/09; A61K038/09+M <--

AB Slow-release **compns.** for inhibiting conception and treating benign gynecol. disorders contain a gonadotropin hormone releasing hormone (GnRH), an estrogen to be released first, in addition to a progestogen and, optionally, an androgen. An. i.m. delivery system for administration over 4 mo contains buserelin, **estradiol**, and progesterone, such that the amount of GnRH is sufficient to suppress LH and FSH secretion during the entire period of administration. Both buserelin and **estradiol** are in the form of glycolide-lactide microspheres.

ST contraceptive slow release; gonadotropin hormone releasing hormone contraceptive; estrogen contraceptive; progestogen contraceptive

IT Androgens
Estrogens
Progestogens
RL: BIOL (Biological study)
(contraceptive slow-release pharmaceuticals containing gonadotropin hormone releasing hormones and)

IT Drug bioavailability
(of contraceptive compds., from slow-release pharmaceuticals)

IT Contraceptives
(slow-release, gonadotropin hormone releasing hormones and estrogens and progestogens and androgens in)

IT Pharmaceutical dosage forms
(slow-release, contraceptives, gonadotropin hormone releasing hormones in)

IT 50-27-1, Estriol **50-28-2**, **Estradiol**, biological studies 50-50-0, **Estradiol** benzoate **53-16-7**, **Estrone**, biological studies 56-53-1, Diethylstilbestrol 57-63-6, Ethinyl **estradiol** 72-33-3, Mestranol 152-43-2, Quinestrol 313-06-4, **Estradiol** cypionate **517-09-9** 979-32-8, **Estradiol** valerate 1240-04-6 7280-37-7, Estropipate 15183-37-6, Estetrol 27651-95-2 28014-46-2, Polyestradiol phosphate 29130-44-7 147827-23-4, Pinestrol
RL: BIOL (Biological study)
(contraceptive slow-release **compns.** containing gonadotropin hormone releasing hormones and, as estrogen)

IT 33515-09-2, Gonadorelin 55599-59-2 57773-63-4, Decapeptyl 57773-65-6, Deslorelin 57982-77-1, Buserelin 65807-02-5, Goserelin 74381-53-6, Leuprolide acetate 76712-82-8 76932-56-4, Nafarelin
RL: BIOL (Biological study)
(contraceptive slow-release pharmaceuticals containing)

IT **53-39-4**, **Oxandrolone** 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-20-8, Testosterone cypionate 58-22-0 62-90-8, Nandrolone phenpropionate 63-05-8, Androstenedione 315-37-7, Testosterone enanthate 360-70-3, Nandrolone decanoate **434-07-1** 521-10-8, Methandriol 521-12-0 521-18-6, Dihydrotestosterone 965-90-2, Ethylestrenol 968-93-4, Testolactone **10418-03-8**, **Stanozolol 17230-88-5**, **Danazol**
RL: BIOL (Biological study)
(contraceptive slow-release pharmaceuticals containing gonadotropin hormone releasing hormone and, as androgen)

IT 51-98-9 68-22-4, Norethindrone 68-23-5, Norethynodrel 71-58-9, Medroxyprogesterone acetate 152-62-5, Dydrogesterone 297-76-7,

Ethynodiol diacetate 595-33-5, Megestrol acetate 630-56-8 6533-00-2, Norgestrel 57-83-0P, Progesterone, preparation
RL: BIOL (Biological study)
(contraceptive slow-release pharmaceuticals containing gonadotropin hormone releasing hormone and, as progestogen)

IT **50-28-2, Estradiol**, biological studies **53-16-7, Estrone**, biological studies **517-09-9**
RL: BIOL (Biological study)
(contraceptive slow-release **compns.** containing gonadotropin hormone releasing hormones and, as estrogen)

RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-16-7 HCAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 517-09-9 HCAPLUS
CN Estra-1,3,5,7,9-pentaen-17-one, 3-hydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **53-39-4, Oxandrolone 434-07-1**
10418-03-8, Stanozolol 17230-88-5,

Danazol
RL: BIOL (Biological study)
(contraceptive slow-release pharmaceuticals containing gonadotropin hormone releasing hormone and, as androgen)
RN 53-39-4 HCAPLUS
CN Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434-07-1 HCAPLUS
CN Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 10418-03-8 HCAPLUS
CN 2'H-Androst-2-eno[3,2-c]pyrazol-17-ol, 17-methyl-, (5α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> => fil medline
FILE 'MEDLINE' ENTERED AT 15:52:50 ON 23 FEB 2005

FILE LAST UPDATED: 22 FEB 2005 (20050222/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

Warning: The search L-number/HUMAN limit is missing from records indexed with the new 2005 MeSH (records added since December 19, 2004). Until this is corrected, include HUMANS/CT and 20041219-20051231/ED in searches to limit results to humans for this time period.

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary. See http://www.nlm.nih.gov/mesh/ and http://www.nlm.nih.gov/pubs/techbull/nd03/nd03_mesh.html for a description of changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot l72

L72 ANSWER 1 OF 9 MEDLINE on STN
AN **94297384** MEDLINE
DN PubMed ID: **8025411**
TI Change in speaking fundamental frequency in hormone-treated patients with Turner's syndrome--a longitudinal study of four cases.
AU Andersson-Wallgren G; Albertsson-Wikland K
CS Department of Logopedics and Phoniatrics, University of Goteborg, Sweden.
SO Acta paediatrica (Oslo, Norway : 1992), **(1994 Apr)** 83 (4) 452-5.
Journal code: 9205968. ISSN: 0803-5253.
CY Norway
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199408
ED Entered STN: 19940818
Last Updated on STN: 19940818
Entered Medline: 19940810
AB Change in speaking fundamental frequency for four hormone-treated girls with Turner's syndrome was registered using two computerized analysis methods for a period of four years. The girls were treated with human

growth hormone, **oxandrolone** and ethinyl **estradiol.**
The overall pattern for three of the girls was a distinct decline in speaking fundamental frequency during the first year, while for the fourth patient the pattern of change was more complicated. For all four girls, the final pitch level was within the normal range for adult women. It is important that voice effects are taken into account in the hormonal treatment of Turner's syndrome and that patients are informed of the changes to be expected.

CT Check Tags: Female; Human; Support, Non-U.S. Gov't
Adolescent
Child
Drug Therapy, Combination
***Ethinyl Estradiol: AD, administration & dosage**
*Growth Hormone: AD, administration & dosage
Longitudinal Studies
***Oxandrolone: AD, administration & dosage**
*Turner Syndrome: DT, drug therapy
*Turner Syndrome: PP, physiopathology
*Voice Quality: DE, drug effects

RN **53-39-4 (Oxandrolone); 57-63-6 (Ethinyl Estradiol);**
9002-72-6 (Growth Hormone)

L72 ANSWER 2 OF 9 MEDLINE on STN
AN **92058173** MEDLINE
DN PubMed ID: **1950723**
TI Alternative treatments in oral postcoital contraception: interim results.
AU Webb A M
CS University of Manchester, Department of Obstetrics and Gynaecology, UK.
SO Advances in contraception : official journal of the Society for the Advancement of Contraception, **(1991 Jun-Sep)** 7 (2-3) 271-9.
Journal code: 8607435. ISSN: 0267-4874.
CY Netherlands
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 199111
ED Entered STN: 19920124
Last Updated on STN: 19920124
Entered Medline: 19911129
AB The study compares the effectiveness and acceptability of three regimes of postcoital contraception: 1) ethinylestradiol 100 micrograms/levonorgestrel 500 micrograms repeated after 12 hours (Yuzpe method); 2) **danazol** 600 mg repeated after 12 hours; and 3) RU486 600 mg single dose. Between 1 April 1990 and 15 October 1990, 215 women were selected and randomly allocated to the three treatment groups. One hundred and sixty eight were fully followed up, 35 ongoing and 8 lost to follow-up. All women had regular cycles and were aged 16-45 years. All treatments were given within 72 hours of unprotected intercourse and follow-up was until normal menstruation or diagnosis of pregnancy. beta-HCG was measured quantitatively where there was a suspicion of pregnancy. The data obtained show similar failure rates (Yuzpe 1/57, **danazol** 2/57, RU486 1/54) but more side-effects in the Yuzpe group (nausea 74.1%, vomiting 22.4%, breast tenderness 22.4%) than in the other two (**danazol**: nausea 31.6%, vomiting 3.5%, breast tenderness 19.3%) and (RU486: nausea 36.4%, vomiting 3.6%, breast tenderness 23.6%). There was one apparent allergic reaction in the **danazol** group. RU486 caused greater cycle disturbance, prolonging the cycle considerably. Initial results suggest that **danazol** and RU486 may be much more acceptable methods of postcoital contraception due to reduced side-effects and, in the latter case, single dose. Although numbers are small at present, the effectiveness of the newer methods appear similar to Yuzpe.

CT Check Tags: Female; Human; Support, Non-U.S. Gov't
Abortifacient Agents: AE, adverse effects
Abortifacient Agents: ST, standards
Adolescent
Adult
*Contraceptives, Oral: TU, therapeutic use
*Contraceptives, Postcoital: ST, standards
Danazol: AE, adverse effects
Danazol: ST, standards
Drug Combinations
Ethinyl Estradiol: AE, adverse effects
Ethinyl Estradiol: ST, standards
Levonorgestrel: AE, adverse effects
Levonorgestrel: ST, standards
Middle Aged
Mifepristone: AE, adverse effects
Mifepristone: ST, standards
Time Factors
RN **17230-88-5 (Danazol); 57-63-6 (Ethinyl Estradiol);** 797-63-7 (Levonorgestrel); 84371-65-3 (Mifepristone)
CN 0 (Abortifacient Agents); 0 (Contraceptives, Oral); 0 (Contraceptives, Postcoital); 0 (Drug Combinations)

L72 ANSWER 3 OF 9 MEDLINE on STN
AN **91301363** MEDLINE
DN PubMed ID: **1830018**
TI Endometrial patterns during **danazol** and cyproterone acetate treatment for endometriosis: structural and ultrastructural study.
AU Marchini M; Fedele L; Bianchi S; Arcaini L; Brioschi D; Di Nola G
CS 1st Department of Obstetrics and Gynecology, University of Milan, Italy.
SO European journal of obstetrics, gynecology, and reproductive biology, **(1991 Jul 1)** 40 (2) 137-43.
Journal code: 0375672. ISSN: 0301-2115.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199108
ED Entered STN: 19910908
Last Updated on STN: 19910908
Entered Medline: 19910822
AB We studied the endometrial structure and ultrastructure in serial biopsies from 16 patients with endometriosis treated with **danazol** (n = 9) or the combination cyproterone acetate plus ethinyl **estradiol** (n = 7) for 6 months. Biopsies were performed before and at 3 and 6 months of treatment. The material obtained was studied by light (LM), scanning (SEM) and transmission electron microscopy (TEM). A morphometric analysis was performed evaluating three morphometric and three stereologic indices. The results indicate that **danazol** had a progestational effect on endometrial glands and stroma, associated with a marked hypotrophy of the mucosa. The cyproterone acetate/ethinyl **estradiol** combination induced progressive atrophy of the endometrium with an increase in the stromal component and a reduction of glandular tissue.
CT Check Tags: Comparative Study; Female; Human
Adult
Biopsy
Cyproterone: AD, administration & dosage
*Cyproterone: AA, analogs & derivatives
Cyproterone: TU, therapeutic use
Cyproterone Acetate
***Danazol: TU, therapeutic use**
Drug Combinations
*Endometriosis: DT, drug therapy

Endometriosis: PA, pathology
Endometrium: DE, drug effects
*Endometrium: PA, pathology
Endometrium: UL, ultrastructure
Estradiol: BL, blood
Ethinyl Estradiol: AD, administration & dosage
***Ethinyl Estradiol: AA, analogs & derivatives**
Ethinyl Estradiol: TU, therapeutic use
Follicle Stimulating Hormone: BL, blood
Luteinizing Hormone: BL, blood
RN 108646-70-4 (ethinyl estriol); **17230-88-5 (Danazol)**; 2098-66-0 (Cyproterone); 427-51-0 (Cyproterone Acetate); **50-28-2 (Estradiol)**; **57-63-6 (Ethinyl Estradiol)**; 9002-67-9 (Luteinizing Hormone); 9002-68-0 (Follicle Stimulating Hormone)
CN 0 (Drug Combinations)

L72 ANSWER 4 OF 9 MEDLINE on STN
AN **91032502** MEDLINE
DN PubMed ID: **2227068**
TI Hormonal postcoital contraception with an ethinylestradiol-norgestrel combination and two **danazol** regimens.
AU Zuliani G; Colombo U F; Molla R
CS AIECS Family Planning Centre, Milan, Italy.
SO European journal of obstetrics, gynecology, and reproductive biology, **(1990 Dec)** 37 (3) 253-60.
Journal code: 0375672. ISSN: 0301-2115.
Report No.: PIP-064397; POP-00199185.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Population
EM 199012
ED Entered STN: 19910208
Last Updated on STN: 20021101
Entered Medline: 19901212
AB The ethinylestradiol-norgestrel combination (EE-NG) for postcoital contraception, as described by Yuzpe, has been shown to be an effective method but with frequent side effects. To overcome the problem of adverse effects a new approach using **danazol** was proposed, but the efficacy and acceptability of this treatment have not yet been tested in large studies. In a 5-year period at the AIECS Family Planning Centre in Milan we treated 2448 women requesting postcoital contraception using Yuzpe's regimen and two **danazol** regimens (800 mg/1200 mg). The patients' acceptability for **danazol** treatment was higher than for Yuzpe's regimen due to fewer, milder and shorter side effects. Nine pregnancies occurred in the EE-NG group (2.21%), 17 in the 800 mg group (1.71%) and 6 in the 1200 mg group (0.82%). Our study shows a statistically significant efficacy against expected pregnancy rates both with Yuzpe's regimen and with **danazol.** The 1200 mg **danazol** treatment seems to be more effective and can be considered a valid alternative to the EE-NG combination for hormonal postcoital contraception. The ethinyl **estradiol**-norgestrel combination (EE-NG) for postcoital contraception as described by Yuzpe has been shown to be an effective method but with frequent side effects. To overcome the problem of adverse effects, a new approach using **danazol** was proposed, but the efficacy and acceptability of this treatment has not yet been put to the test in larger groups. In a 5-year period at the AIECS Family Planning Center in Milan, the authors treated 2448 women requesting postcoital contraceptives using Yuzpe's regimen and 2 **danazol** regimens (800 mg/1200 mg). The **danazol** treatment met with a greater measure of patient acceptability than did Yuzpe's regimen, due mainly to the smaller number of side effects. 9 pregnancies occurred in the EE-NG group (2.21%), 17 in the 800 mg group (1.71%), and 6 in the 1200

mg group (0.82%). This study shows a statistically significant efficacy against expected pregnancy rates, both with Yuzpe's regimen and with **danazol**. The 1200 mg **danazol** treatment seems to be more effective and can be considered a valid alternative to the EE-NG combination for hormonal postcoital contraception.
author's modified

ST Age Distribution; Age Factors; Clinical Research; Comparative Studies; Contraception; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Contraceptive Usage; Data Collection; Demographic Factors; Developed Countries; Diseases; Ethinyl **Estradiol**--administraction and dosage; Ethinyl **Estradiol**--side effects; Europe; Family Planning; Fertility; Fertility Control, Postcoital; Fertility Measurements; Follow-up Studies; Italy; Mediterranean Countries; Method Acceptability; Norgestrel--administraction and dosage; Norgestrel--side effects; Parity; Population; Population Characteristics; Population Dynamics; Pregnancy Rate; Research Methodology; Signs And Symptoms; Southern Europe; Studies

CT Check Tags: Comparative Study; Female; Human
Adolescent
Adult
*Contraceptives, Postcoital, Hormonal
Contraceptives, Postcoital, Hormonal: AE, adverse effects
***Danazol: AD, administration & dosage**
Drug Administration Schedule
Drug Combinations
***Ethinyl Estradiol: AD, administration & dosage**
*Norgestrel: AD, administration & dosage
Pregnancy

RN **17230-88-5 (Danazol); 57-63-6 (Ethinyl Estradiol);** 6533-00-2 (Norgestrel)

CN 0 (Contraceptives, Postcoital, Hormonal); 0 (Drug Combinations)

L72 ANSWER 5 OF 9 MEDLINE on STN

AN **90093148** MEDLINE

DN PubMed ID: **2689306**

TI [Hormone therapy of endometriosis].
Hormontherapie der Endometriose.

AU Distler W

CS Universitats-Frauenklinik Dusseldorf.

SO Der Gynakologe, **(1989 Oct)** 22 (5) 294-301. Ref: 57
Journal code: 0410275. ISSN: 0017-5994.

CY GERMANY, WEST: Germany, Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)

LA German

FS Priority Journals

EM 199002

ED Entered STN: 19900328
Last Updated on STN: 19900328
Entered Medline: 19900202

CT Check Tags: Female; Human
Danazol: TU, therapeutic use
Drug Therapy, Combination
*Endometriosis: DT, drug therapy
Estradiol Congeners: TU, therapeutic use
*Genital Neoplasms, Female: DT, drug therapy
*Hormones: TU, therapeutic use

Pituitary Hormone-Releasing Hormones: TU, therapeutic use
Progesterone Congeners: TU, therapeutic use
RN **17230-88-5 (Danazol)**
CN 0 (**Estradiol** Congeners); 0 (Hormones); 0 (Pituitary Hormone-Releasing Hormones); 0 (Progesterone Congeners)

L72 ANSWER 6 OF 9 MEDLINE on STN
AN **90052449** MEDLINE
DN PubMed ID: **2816362**
TI Effect of recombinant human growth hormone therapy on bone and clinical parameters in girls with Turner's syndrome. The Spanish Collaborative Group.
AU Ferrandez A; Mayayo E; Arnal J M; Garcia C; Bunuel C; Lasarte J J; Anton R; Puyuelo P
CS Endocrine Unit, Children's Hospital, Zaragoza, Spain.
SO Acta paediatrica Scandinavica. Supplement, **(1989)** 356 87-91; discussion 92.
Journal code: 0173166. ISSN: 0300-8843.
CY Sweden
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198912
ED Entered STN: 19900328
Last Updated on STN: 19900328
Entered Medline: 19891205
AB Forty-eight girls with Turner's syndrome were assigned to one of three treatments; recombinant human growth hormone (rhGH) alone, rhGH plus **oxandrolone**, and rhGH plus ethinyloestradiol. Treatment with rhGH alone or in combination with **oxandrolone** induced catch-up growth. Older girls treated with rhGH plus ethinyloestradiol showed less marked improvement. The gain in height was associated with a gain in bone diameter and cortical thickness (reflecting increased bone mass). There was a rapid loss of subcutaneous fat. These effects of growth hormone are similar to those observed in patients with growth hormone deficiency.
CT Check Tags: Female; Human
Adolescent
*Bone Development: DE, drug effects
Child
Child, Preschool
Drug Therapy, Combination
Ethinyl Estradiol: TU, therapeutic use
*Growth Disorders: DT, drug therapy
*Growth Hormone: TU, therapeutic use
Oxandrolone: TU, therapeutic use
Recombinant Proteins
Skinfold Thickness
*Turner Syndrome: CO, complications
RN **53-39-4 (Oxandrolone); 57-63-6 (Ethinyl Estradiol);** 9002-72-6 (Growth Hormone)
CN 0 (Recombinant Proteins)

L72 ANSWER 7 OF 9 MEDLINE on STN
AN **89239508** MEDLINE
DN PubMed ID: **2654820**
TI [The current treatment concept of Turner syndrome]. Aktuelles Behandlungskonzept des Turner-Syndroms.
AU Blumel P; Stogmann W
CS Gottfried von Preyersches Kinderspital der Stadt Wien.
SO Padiatrie und Padologie, **(1989)** 24 (1) 81-9. Ref: 36
Journal code: 0022370. ISSN: 0030-9338.
CY Austria
DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA German
FS Priority Journals
EM 198906
ED Entered STN: 19900306
Last Updated on STN: 19900306
Entered Medline: 19890609
AB Turner's Syndrome (XO Karyotype or XO/XX mosaicism) affects 1 in 2500 females. It results in short stature (mean adult height is about 146 cm), infertility and the lack of secondary sexual characteristics. Hormone replacement therapy to develop secondary sexual characteristics has been used for years whereas several growth promoting agents undergo clinical trials at the moment. Our current management for patients with Turner's Syndrome includes the induction of puberty at a bone age of 11 to 12 years with low dose oestradiol and the application of biosynthetic human growth hormone (hGH) when growth velocity falls below the normal range. In our group of previously untreated patients (4.6-14 years) one year results of hGH application (12-18 IU/m2/week 7 equal doses sc/week) show a clear improvement of growth velocity (3.43 + 0.44 cm/year before therapy versus 6.2 + 1.14 cm/year after the first year of treatment, p less than 0.001). The growth promoting effect of hGH therapy might further be improved by the combination with anabolic steroids like oxandrolon.
CT Check Tags: Female; Human
Adolescent
Body Height: DE, drug effects
Child
Drug Therapy, Combination
English Abstract
Estradiol: AD, administration & dosage
Ethinyl Estradiol: AD, administration & dosage
Growth Hormone: AD, administration & dosage
Oxandrolone: AD, administration & dosage
*Turner Syndrome: TH, therapy
RN **50-28-2 (Estradiol)**; **53-39-4 (Oxandrolone)**; **57-63-6 (Ethinyl Estradiol)**; 9002-72-6 (Growth Hormone)

L72 ANSWER 8 OF 9 MEDLINE on STN
AN **86005552** MEDLINE
DN PubMed ID: **3850029**
TI [Endometriosis].
Endometrioz.
AU Kiriushchenkov A P
SO Fel'dsher i akusherka, **(1985 Jul)** 50 (7) 14-21.
Journal code: 16930040R. ISSN: 0014-9772.
CY USSR
DT Journal; Article; (JOURNAL ARTICLE)
LA Russian
FS Nursing Journals
EM 198511
ED Entered STN: 19900321
Last Updated on STN: 19900321
Entered Medline: 19851115
CT Check Tags: Female; Human
*Cervix Neoplasms: DI, diagnosis
Cervix Neoplasms: TH, therapy
Danazol: TU, therapeutic use
Drug Combinations
*Endometriosis: DI, diagnosis
Endometriosis: TH, therapy
English Abstract
Estradiol Congeners: TU, therapeutic use
*Ovarian Neoplasms: DI, diagnosis

Ovarian Neoplasms: TH, therapy
RN **17230-88-5 (Danazol)**
CN 0 (Drug Combinations); 0 (**Estradiol** Congeners)

L72 ANSWER 9 OF 9 MEDLINE on STN
AN **84263633** MEDLINE
DN PubMed ID: **6146575**
TI Open forum: Diagnosis and treatment of endometriosis.
AU Anonymous
SO International journal of fertility, **(1984)** 29 (1) 1-9.
Journal code: 0374717. ISSN: 0020-725X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198409
ED Entered STN: 19900320
Last Updated on STN: 19950206
Entered Medline: 19840907
CT Check Tags: Female; Human
Danazol: TU, therapeutic use
Drug Therapy, Combination
*Endometriosis
Endometriosis: DI, diagnosis
Endometriosis: DT, drug therapy
Endometriosis: SU, surgery
***Estradiol Congeners: TU, therapeutic use**
Hysterectomy
Laparoscopy
Medroxyprogesterone: TU, therapeutic use
*Pelvic Neoplasms
Pelvic Neoplasms: DI, diagnosis
Pelvic Neoplasms: DT, drug therapy
Pelvic Neoplasms: SU, surgery
*Progesterone Congeners: TU, therapeutic use
RN **17230-88-5 (Danazol)**; 520-85-4 (Medroxyprogesterone)
CN 0 (**Estradiol** Congeners); 0 (Progesterone Congeners)

=> d his

(FILE 'HOME' ENTERED AT 15:05:26 ON 23 FEB 2005)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 15:05:33 ON 23 FEB 2005
L1 1 S US20020151530/PN OR (US2001-029424# OR WO2001-US51045 OR US20
E LEONARD T/AU
L2 54 S E3,E15,E24,E25,E30
E WALDON R/AU
L3 5 S E4,E6
E ENDEAVOR/PA,CS
L4 23 S E3-E17

FILE 'REGISTRY' ENTERED AT 15:13:15 ON 23 FEB 2005
L5 1 S 53-16-7
L6 1 S 474-86-2
L7 1 S 474-87-3
L8 1 S 57-91-0
L9 1 S 3563-27-7
L10 1 S 651-55-8
L11 1 S 50-28-2
L12 1 S 517-09-9
L13 1 S 6639-99-2

```
L14           1 S 1423-97-8
L15          10 S L5-L14
                SEL RN
L16         185 S E1-E10/CRN
L17           1 S 53-39-4
L18           1 S 434-07-1
L19           1 S 10418-03-8
L20           1 S 17230-88-5
L21           4 S L17-L20
                SEL RN
L22          13 S E11-E14/CRN
L23           0 S L16 AND L22

     FILE 'HCAPLUS' ENTERED AT 15:17:00 ON 23 FEB 2005
L24       58199 S L15
L25       31491 S ESTRONE OR EQUILIN OR DELTA 8 9 DEHYDROESTERONE OR (17A OR 17
L26       73257 S ESTRADIOL
L27          85 S (17A OR 17ALPHA OR 17B OR 17BETA OR 17()(ALPHA OR BETA))()OES
L28       81641 S L24-L27
L29        1451 S L21
L30        1378 S OXANDROLONE OR OXYMETHOLONE OR STANOZOLOL OR DANAZOL
L31        1614 S L29,L30
L32         316 S L28 AND L31
L33         268 S L32 AND (PD<=20001222 OR PRD<=20001222 OR AD<=20001222 OR PY<
                E HORMONE REPLACEMENT THERAPY/CT
                E E3+ALL
L34        3632 S E4
L35        5515 S E4-E6/BI
L36        3660 S HRT
L37           5 S L33 AND L34-L36
                E MENOPAUSE/CT
L38        9435 S E3-E12
                E E3+ALL
L39       12388 S E4,E5/BI
L40       18481 S ?MENOPAUS?
L41          16 S L33 AND L38-L40
L42          18 S L37,L41
L43           5 S L1-L4 AND L32
L44          89 S L33 AND (UTERUS OR UTERIN? OR VAGINA OR VAGINAL)
                E SEX/CT
                E E3+ALL
L45           6 S L33 AND E2+NT
                E E11+ALL
L46           7 S L33 AND E3+OLD,NT
L47          31 S L42,L43,L45,L46
L48          26 S L47 NOT L43
L49          19 S L48 AND L24 AND L29
                SEL DN AN 6 7
L50           2 S L49 AND E1-E6
L51          17 S L49 NOT L50
                SEL DN AN 2 5 6
L52           3 S L51 AND E7-E15
L53           7 S L47 NOT L49,L43
L54          79 S L44 NOT L43,L45-L53
                SEL DN AN 26
L55           1 S L54 AND E16-E18
L56           9 S L43,L52,L55
L57          40 S L33 AND COMPOSITION
L58          35 S L57 NOT L56
                SEL DN AN 6 8 11 15
L59           4 S L58 AND E19-E30
L60          13 S L56,L59 AND L1-L4,L24-L59
```

```
     FILE 'REGISTRY' ENTERED AT 15:44:50 ON 23 FEB 2005

     FILE 'HCAPLUS' ENTERED AT 15:46:15 ON 23 FEB 2005

     FILE 'MEDLINE' ENTERED AT 15:46:59 ON 23 FEB 2005
L61       59194 S L15
L62       79897 S L25 OR L26 OR L27
L63         137 S EQUILENIN
L64       79939 S L61-L63
L65        2900 S L21
L66        3496 S L30
L67         322 S L64 AND L65,L66
L68         309 S L67 AND PY<=2000
                E DRUG COMBINATION/CT
                E E6+ALL
L69       39026 S E3
                E DRUG THERAPY, COMBINATION/CT
                E E3+ALL
L70       79604 S E4
                E E5+ALL
L71          17 S L68 AND L69,L70
                SEL DN AN 4 6 7 8 9 10 13 14 16
L72           9 S L71 AND E1-E18
                E HORMONE REPLACEMENT THERAPY/CT
                E E3+ALL
L73        3127 S E4
L74        9250 S E12
L75           1 S L68 AND L73,L74

     FILE 'MEDLINE' ENTERED AT 15:52:50 ON 23 FEB 2005

=>
```